<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of postpartum hemorrhage
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of postpartum hemorrhage
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of postpartum hemorrhage
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael A Belfort, MBBCH, MD, PhD, D.A. (SA), FRCSC, FRCOG, FACOG
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Dena Goffman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vanessa A Barss, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 18, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postpartum hemorrhage (PPH) is an obstetric emergency. It is one of the top five causes of maternal mortality in both resource-abundant and resource-limited countries, although the absolute risk of death from PPH is much lower in the former. Timely recognition, availability of appropriate resources, and appropriate response are critical for preventing death and severe maternal morbidity. Provider and institutional planning and preparation are essential to ensure an appropriate response.
        </p>
        <p>
         This topic will present an overview of major issues relating to PPH. Clinical use of specific medical and minimally invasive interventions, and surgical interventions at laparotomy, for management of PPH are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6712.html" rel="external">
          "Postpartum hemorrhage: Management approaches requiring laparotomy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3044772299">
         <span class="h1">
          TERMINOLOGY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary or early PPH
         </strong>
         refers to PPH occurring in the first 24 hours after giving birth and is the subject of this topic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary, late, or delayed PPH
         </strong>
         refers to PPH occurring from 24 hours to 12 weeks after birth and is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/113133.html" rel="external">
          "Secondary (late) postpartum hemorrhage"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1069308967">
         <span class="h1">
          CRITERIA FOR DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H4253668721">
         <span class="h2">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         We make the diagnosis of PPH in postpartum patients with bleeding that is greater than expected and results in signs and/or symptoms of hypovolemia  (
         <a class="graphic graphic_table graphicRef56885" href="/z/d/graphic/56885.html" rel="external">
          table 1
         </a>
         ). Some patients will have signs and/or symptoms of hypovolemia before excessive blood loss is seen because the bleeding is intraabdominal, retroperitoneal, or in the pelvic floor (eg, vaginal hematoma).
        </p>
        <p>
         Excessive blood loss can be inferred from large studies evaluating uterotonic drugs for prevention of PPH. In such studies, at vaginal birth, less than 10 percent of patients receiving routine prophylaxis against PPH had blood loss ≥500 mL and less than 2 percent had blood loss ≥1000 mL [
         <a href="#rid1">
          1
         </a>
         ]; at cesarean birth, 63 percent had blood loss &gt;500 mL and 30 percent had blood loss &gt;1000 mL [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3170515325">
         <span class="h2">
          Other criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Various criteria for diagnosis of PPH are in use worldwide, as shown in the table  (
         <a class="graphic graphic_table graphicRef113123" href="/z/d/graphic/113123.html" rel="external">
          table 2
         </a>
         ). Although some guidelines utilize the classic definition of PPH for diagnosis (ie, estimated blood loss [EBL] ≥500 mL after vaginal birth or ≥1000 mL after cesarean birth), this is problematic because bleeding may not be visible externally, blood in collection devices may be mixed with amniotic fluid, and postpartum morbidity is relatively infrequent among patients with blood loss of 500 to 999 mL [
         <a href="#rid3">
          3
         </a>
         ]. Because of these limitations, the American College of Obstetricians and Gynecologists (ACOG) revised their definition of PPH in 2017 to the following [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cumulative blood loss ≥1000 mL,
         <strong>
          or
         </strong>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bleeding associated with signs/symptoms of hypovolemia within 24 hours of the birth process
        </p>
        <p>
        </p>
        <p>
         The criteria apply to both vaginal and cesarean birth. However, ACOG emphasized that despite this updated definition, a blood loss greater than 500 mL in a vaginal birth should be considered abnormal, particularly if heavy bleeding persists, and should prompt evaluation and close monitoring by the health care provider.
        </p>
        <p class="headingAnchor" id="H3811883508">
         <span class="h2">
          Classification of severity
         </span>
        </p>
        <p class="headingAnchor" id="H2977086173">
         <span class="h3">
          California Maternal Quality Care Collaborative staging system
         </span>
         <span class="headingEndMark">
          —
         </span>
         The California Maternal Quality Care Collaborative (CMQCC) obstetric hemorrhage toolkit describes the following stages of PPH and level of intervention for each stage [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage 0 – Every patient in labor/giving birth
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intervention: Prophylactic
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         , quantitate cumulative blood loss, closely monitor
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage 1 – Cumulative blood loss ≥500 mL at vaginal birth or ≥1000 mL at cesarean birth with continued bleeding or
         <strong>
         </strong>
         signs of concealed hemorrhage, such as vital signs that are abnormal or trending in that direction (heart rate ≥110 beats per minute [bpm], blood pressure ≤85/45 mmHg, O
         <sub>
          2
         </sub>
         saturation &lt;95%, shock index [SI] 0.9) or
         <strong>
         </strong>
         confusion
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intervention: Activate institutional PPH protocol
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage 2 – Continued bleeding or vital sign instability, and cumulative blood loss &lt;1500 mL
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intervention: Begin next level of interventions in the institutional PPH protocol, mobilize PPH rapid response team and blood bank support
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage 3 – Continued bleeding, with cumulative blood loss &gt;1500 mL or transfusion of &gt;2 units of red blood cells or abnormal vital signs or suspicion of disseminated intravascular coagulation
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intervention: Move on to next level of interventions in the institutional PPH protocol, initiate massive transfusion protocol and surgical approaches for control of hemorrhage
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3796693398">
         <span class="h3">
          Advanced trauma life support classification
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Advanced Trauma Life Support manual describes four classes of hemorrhage to emphasize the progressive signs and symptoms leading to shock [
         <a href="#rid6">
          6
         </a>
         ]. The following classes were derived from nonpregnant populations and thus may be somewhat different in postpartum patients, but remain useful:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Class I hemorrhage involves a blood volume loss of up to 15 percent. The heart rate is minimally elevated or normal, and there is no change in blood pressure, pulse pressure, or respiratory rate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Class II hemorrhage involves a blood volume loss of 15 to 30 percent. It manifests clinically as tachycardia (heart rate of 100 to 120 bpm), tachypnea (respiratory rate of 20 to 24 breaths per minute), and decreased pulse pressure, although systolic blood pressure changes minimally, if at all. The skin may be cool and clammy, and capillary refill may be delayed. An increasing maternal heart rate and tachypnea with stable systolic blood pressure should be regarded as evidence of compensated shock and should prompt investigation and institution of a PPH protocol, even if only light vaginal bleeding is observed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Class III hemorrhage involves a blood volume loss of 30 to 40 percent, resulting in a significant drop in blood pressure and changes in mental status. Any hypotension (systolic blood pressure less than 90 mmHg) or drop in blood pressure greater than 20 to 30 percent of the measurement at presentation is cause for concern. While diminished anxiety or pain may contribute to such a drop, the clinician must assume it is due to hemorrhage until proven otherwise. Heart rate (≥120 bpm and "thready") and respiratory rate are markedly elevated, while urine output is diminished. Capillary refill is delayed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Class IV hemorrhage involves a blood volume loss of &gt;40 percent, leading to significant depression in blood pressure and mental status. Most patients are hypotensive (systolic blood pressure less than 90 mmHg). Pulse pressure is narrowed (≤25 mmHg), and tachycardia is marked (&gt;120 bpm). Urine output is minimal or absent. The skin is cold and pale, and capillary refill is delayed.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H100822707">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         PPH is generally reported to occur in 1 to 3 percent of births [
         <a href="#rid7">
          7-9
         </a>
         ]. In an analysis of population-based data from the United States National Inpatient Sample, the PPH rate increased from 2.7 percent in 2009 to 4.3 percent in 2019 [
         <a href="#rid9">
          9
         </a>
         ]. However, many reports are based on subjective estimates of blood loss; when blood loss is measured quantitatively, prospective studies have reported postpartum blood loss ≥500 mL in as many as 10 percent of births [
         <a href="#rid10">
          10
         </a>
         ]. Variations in criteria for PPH (eg, &gt;500 versus &gt;1000 mL, presence/absence of symptoms) also contribute to variations in reported incidence.
        </p>
        <p>
         Population-based surveillance data show an increasing frequency of severe PPH in the US [
         <a href="#rid11">
          11
         </a>
         ]. This is likely related to increased rates of cesarean birth and the increased risk of placenta previa and placenta accreta spectrum (PAS) in patients with a prior cesarean birth.
        </p>
        <p>
         Higher rates of PPH have been reported in some races/ethnicities [
         <a href="#rid12">
          12
         </a>
         ], but race/ethnicity is not a biologic construct and does not make an individual physiologically at higher risk for hemorrhage [
         <a href="#rid5">
          5
         </a>
         ]. The higher rate in some races/ethnicities has been attributed to disparities in quality of care.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          PHYSIOLOGIC MECHANISMS THAT LIMIT POSTPARTUM BLOOD LOSS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Normally, hemostasis occurs upon placental separation because uterine bleeding is controlled by a combination of two mechanisms:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mechanical hemostasis, whereby contraction of the myometrium compresses the blood vessels supplying the placental bed, resulting in severely reduced blood flow.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Local thrombosis, whereby the presence or release of local decidual hemostatic factors (tissue factor [
         <a href="#rid13">
          13,14
         </a>
         ] and type-1 plasminogen activator inhibitor, respectively [
         <a href="#rid15">
          15,16
         </a>
         ]) and systemic coagulation factors (eg, platelets, circulating clotting factors) lead to thrombosis of damaged blood vessels supplying the placental bed, resulting in severely reduced blood flow.
        </p>
        <p>
        </p>
        <p>
         Abnormalities in these normal physiologic mechanisms have a high potential for massive hemorrhage because in late pregnancy, uterine artery blood flow is 500 to 700 mL/min (versus 60 mL/min in the nonpregnant state) and accounts for approximately 15 percent of cardiac output.
        </p>
        <p class="headingAnchor" id="H1697502600">
         <span class="h1">
          RISK FACTORS FOR PPH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many risk factors for PPH have been reported and are often interdependent  (
         <a class="graphic graphic_table graphicRef141269" href="/z/d/graphic/141269.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid17">
          17-32
         </a>
         ]. Identification of most of these risk factors is of limited usefulness because of low-positive and negative predictive value for PPH. (See
         <a class="local">
          'PPH risk assessment tools and risk-based preparation'
         </a>
         below.)
        </p>
        <p>
         The odds of several risk factors in two large series are described below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of over 154,000 births comparing 666 cases of PPH with controls without hemorrhage, factors significantly associated with hemorrhage were, in decreasing order of frequency [
         <a href="#rid33">
          33
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Retained placenta/membranes (odds ratio [OR] 3.5, 95% CI 2.1-5.8)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Failure to progress during the second stage of labor (OR 3.4, 95% CI 2.4-4.7)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Placenta accreta spectrum (PAS; OR 3.3, 95% CI 1.7-6.4)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lacerations (OR 2.4, 95% CI 2.0-2.8)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Forceps- or vacuum-assisted vaginal birth (OR 2.3, 95% CI 1.6-3.4)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Large for gestational age newborn (eg, &gt;4000 g; OR 1.9, 95% CI 1.6-2.4)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypertensive disorders (preeclampsia, eclampsia, HELLP [Hemolysis, Elevated Liver enzymes, Low Platelets]) (OR 1.7, 95% CI 1.2-2.1)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Induction of labor (OR 1.4, 95% CI 1.1-1.7)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prolonged first or second stage of labor (OR 1.4, 95% CI 1.2-1.7)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of over 690,000 births, the four risk factors associated with the highest odds for predicting the need for massive transfusion (406 cases) during hospitalization for delivery were [
         <a href="#rid34">
          34
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Abnormal placentation (placenta accreta or previa 1.6 in 10,000 births, adjusted OR [aOR] 18.5, 95% CI 14.7-23.3)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Placental abruption (1.0 in 10,000 births, aOR 14.6, 95% CI 11.2-19.0)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe preeclampsia (0.8 in 10,000 births, aOR 10.4, 95% CI 7.7-14.2)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fetal demise (0.7 in 10,000 births, aOR 5.5, 95% CI 3.9-7.8)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H100822458">
         <span class="h1">
          CAUSES OF POSTPARTUM HEMORRHAGE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common causes of PPH can be considered using the Four Ts mnemonic [
         <a href="#rid35">
          35
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tone: uterine atony
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Trauma: laceration, rupture
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tissue: retained tissue, blood clots, or placenta accreta spectrum (PAS)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombin: coagulopathy
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H100823213">
         <span class="h2">
          Focal or diffuse atony
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uterine atony (ie, lack of effective uterine contraction after birth) prevents mechanical hemostasis from occurring and is responsible for at least 80 percent of cases of PPH; it complicates approximately 1 in 40 births in the United States [
         <a href="#rid36">
          36
         </a>
         ]. Although diffuse uterine atony is the most common cause of PPH, it is often responsive to administration of uterotonic medications; thus, it is not the most common reason for massive intrapartum or postpartum transfusion [
         <a href="#rid17">
          17
         </a>
         ]. Nevertheless, atony-related PPH is the indication for 27 percent of peripartum hysterectomies [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Atony is diagnosed when the uterus does not become firm to palpation after expulsion of the placenta. Administration of prophylactic uterotonic medications after birth is standard practice worldwide to prevent atony. (See
         <a class="medical medical_review" href="/z/d/html/4437.html" rel="external">
          "Management of the third stage of labor: Prophylactic pharmacotherapy to minimize hemorrhage"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         With diffuse atony, the flaccid, dilated uterus may contain a significant amount of blood so blood loss can be much greater than observed. With focal localized atony, the fundal region may be well contracted while the lower uterine segment is dilated (ballooned) and atonic, which is difficult to appreciate on abdominal examination, but may be detected on vaginal examination.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors for atony
         </strong>
         – Prior PPH and prolonged labor are the most well-established risk factors for atony-related PPH [
         <a href="#rid38">
          38
         </a>
         ]. Other risk factors include chorioamnionitis, therapeutic use of
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         , labor induction or augmentation, fibroids, or uterine overdistention from multiple gestation, macrosomia, or polyhydramnios. Uterine inversion can be associated with fundal atony, even though there is constriction of the lower uterine segment/cervix.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H100823219">
         <span class="h2">
          Trauma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Trauma-related bleeding can be due to lacerations (including complete or partial myometrial rupture [
         <a href="#rid39">
          39
         </a>
         ]) or surgical incisions. Cervical and vaginal lacerations may occur from natural processes during birth or as a result of provider interventions. In a series of 349 cases of massive PPH (ie, &gt;2500 mL and/or ≥5 units red blood cell transfusion), trauma was the most common cause and accounted for 55 percent of cases compared with 23 percent for atony alone [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Tissue trauma after a vaginal birth is diagnosed on physical examination but may not be noted until excessive postpartum vaginal bleeding prompts careful examination of the lower genital tract beyond the perineum, including examination for vaginal and vulvar hematomas and cervical lacerations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         At cesarean birth, hemorrhage from the uterine incision is generally caused by lateral extension of the incision, which can result from spontaneous tearing of an edematous lower uterine segment during an otherwise uneventful cesarean after prolonged labor, from an incision made too low or not sufficiently curved on the lower segment, or from delivery of the fetus through an incision that is too small. Bleeding from lateral extension of the uterine incision is readily ascertained by inspecting the incision, lateral pelvic sidewalls, and broad ligament. Retroperitoneal enlargement and bulging of the broad ligament at cesarean birth can be signs of retroperitoneal hemorrhage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Bleeding can also occur as a result of uterine rupture, which may be anterior, lateral, or posterior. (See
         <a class="medical medical_review" href="/z/d/html/14210.html" rel="external">
          "Uterine rupture: Unscarred uterus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/87237.html" rel="external">
          "Uterine rupture: After previous cesarean birth"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors for trauma
         </strong>
         – Risk factors for severe perineal trauma during vaginal birth include instrument-assisted vaginal birth, midline episiotomy, and persistent occiput posterior position [
         <a href="#rid41">
          41
         </a>
         ]. In cesarean births, delivery after full dilation is a risk factor for unintended uterine incision extension, particularly in the setting of past cesarean birth or failed vacuum attempt [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2645772963">
         <span class="h2">
          Placental disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Placental disorders, such as PAS, placenta previa, abruption, and retained placenta, cause PPH because effective uterine contraction and hemostasis of decidual vessels is inhibited, either focally or diffusely. In addition, abruption can trigger disseminated intravascular coagulation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Placenta previa and PAS are typically diagnosed prenatally by ultrasound. The diagnosis of abruption is primarily based on history and physical examination; laboratory studies showing coagulopathy support the diagnosis. Retained placenta is diagnosed when the placenta has not been expelled within 30 minutes of birth.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – There are multiple risk factors for occurrence of a placental disorder. Prior cesarean birth is a risk factor for placenta previa and PAS. Hypertension is a risk factor for abruption. Uterine anomalies are a risk factor for retained placenta.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6759.html" rel="external">
          "Placenta accreta spectrum: Clinical features, diagnosis, and potential consequences"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6772.html" rel="external">
          "Placenta previa: Epidemiology, clinical features, diagnosis, morbidity and mortality"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15333.html" rel="external">
          "Retained placenta after vaginal birth"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6826.html" rel="external">
          "Acute placental abruption: Pathophysiology, clinical features, diagnosis, and consequences"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H100823243">
         <span class="h2">
          Coagulopathy or other bleeding diathesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Coagulopathy (reduced hemostasis) complicates approximately 1 in 500 births in the United States and is responsible for up to 7 percent of cases of PPH [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         In patients with an inherited or acquired bleeding diathesis, coagulopathy or platelet dysfunction can cause PPH.
        </p>
        <p>
         In patients without an inherited or acquired bleeding diathesis, consumption and hemodilution of clotting factors during PPH can severely impair clotting and exacerbate bleeding. However, coagulopathy is a late finding in these cases. In a study including &gt;18,000 patients with ≥1500 mL blood loss at birth, the median prothrombin time (PT) was 12.3 seconds, the longest activated partial thromboplastin time (aPTT) was 30.4 seconds, and the lowest fibrinogen was 360 mg/dL; all of these values are within the normal range for pregnancy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – In acute PPH, coagulopathy should be suspected in patients with one or more of the following: low fibrinogen level (&lt;300 mg/dL), thrombocytopenia (&lt;100,000/microL), prolonged PT (international normalized ratio [INR] &gt;1.5), and/or prolonged aPTT (varies by laboratory).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Thromboelastography (TEG)/Rotational Thromboelastometry (ROTEM), where available, provides a global assessment of hemostasis in whole blood that includes contributions of platelets, fibrinogen, fibrinolysis, and coagulation factors. It can be particularly useful for diagnosing dilutional coagulopathy. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Viscoelastic testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors for coagulopathy
         </strong>
         – Acute acquired coagulopathies can be caused by amniotic fluid embolism, placental abruption, preeclampsia with severe features, HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets), sepsis, or fetal demise. Patients with von Willebrand disease (VWD) are at increased risk for PPH because VWD factor levels, which typically increase during pregnancy, decline rapidly after birth. After an acute PPH event, an evaluation for VWD factor and platelet function may be warranted. (See
         <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">
          "Approach to the adult with a suspected bleeding disorder"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          INSTITUTIONAL PLANNING AND PREPARATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Institutional planning and preparation take a proactive rather a reactive approach to PPH response [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3621779344">
         <span class="h2">
          Patient education
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients should receive verbal and printed educational material about PPH since most PPHs occur in low-risk patients and PPH may occur after hospital discharge [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="local">
          'Postpartum care'
         </a>
         below and
         <a class="local">
          'Information for patients'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2415041122">
         <span class="h2">
          PPH risk assessment tools and risk-based preparation
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk assessment
         </strong>
         – In the United States, The Joint Commission requires use of an evidence-based tool for determining maternal hemorrhage risk both on admission to labor and delivery and on admission to a postpartum unit [
         <a href="#rid43">
          43
         </a>
         ], but does not provide specific tools for risk assessment and management. The California Maternal Quality Care Collaborative (CMQCC) recommends intrapartum obstetric hemorrhage risk assessment on admission to the labor unit, at the start of the second stage of labor, at transfer to postpartum care, and any time the patient's condition changes [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Knowledge of risk factors for PPH and risk assessment tools have limited utility because many patients without risk factors experience severe PPH (eg, 40 percent of patients with PPH in one study had no risk factors [
         <a href="#rid17">
          17
         </a>
         ]) [
         <a href="#rid26">
          26,44
         </a>
         ] and most high-risk patients do not experience significant hemorrhage (risk of severe hemorrhage ranges from 2 to 7 percent [
         <a href="#rid44">
          44-46
         </a>
         ]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A systematic review of 14 prognostic models for PPH found that none were sufficiently validated in the general obstetric population, and three were potentially useful in high-risk populations (patients undergoing cesarean birth, patients with placenta previa or placenta accreta spectrum [PAS]) [
         <a href="#rid47">
          47
         </a>
         ]. A retrospective study comparing the predictive value of the CMQCC, American College of Obstetricians and Gynecologists Safe Motherhood Initiative (ACOG SMI), and Association of Women's Health, Obstetric and Neonatal Nurses (AWOHNN), PPH risk stratification tools in over 11,000 patients admitted to the labor and delivery unit found that none performed well for predicting significant PPH within 48 hours after birth (defined as transfusion of at least one unit of red blood cells) [
         <a href="#rid46">
          46
         </a>
         ]. Although high-risk patients had a higher incidence of significant PPH than low-risk patients, less than 5 percent of high-risk patients developed significant PPH (3.9-4.6 percent versus 1.5-1.8 percent in low-risk patients).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Despite the low predictive value of current risk assessment tools, use of a tool is likely better than no risk assessment as the risk stratification process may raise consciousness and preparation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tools
         </strong>
         – Several tools for risk assessment and risk-based management have been developed. Disadvantages of some prognostic models is that they apply to narrow patient populations, are overly complex for routine use, or include variables that are not routinely available or known after PPH has most likely occurred [
         <a href="#rid48">
          48
         </a>
         ]. The advantage of the CMQCC tool and its derivatives are that they apply to the general obstetric population, can be administered by a labor and delivery nurse, include ongoing risk assessment, and can be embedded in the electronic health record:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CMQCC
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cmqcc.org%2Fresources-tool-kits%2Ftoolkits%2Fob-hemorrhage-toolkit&amp;token=Fy7OONGXYS0fkPZpZMq%2B%2FT%2FfpTqt%2BPWZAdPlPf9WBSrYGkq0mZbCyT7ovL4gDJij9VdckOV520er6Oo2f51dc03FjSTEkUrfQ%2FWtHQlNRJE%3D&amp;TOPIC_ID=6710" target="_blank">
          toolkit
         </a>
         . The CMQCC risk classification scheme is used initially for patients admitted to the labor unit [
         <a href="#rid5">
          5
         </a>
         ]. Although it classifies patients as low, medium, or high risk for PPH, in a validation study of an earlier version (version 1.0 in 2010), the incidence of severe PPH (ie, necessitating transfusion) in the three groups was 0.8, 2.0, and 7.3 percent, respectively, and only 22 percent of severe PPH cases occurred in the high-risk group [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The CMQCC tool also provides for ongoing risk assessment by including intrapartum and postpartum risk factors in the checklist (eg, retained placenta, cesarean or operative vaginal birth, 3
         <sup>
          rd
         </sup>
         or 4
         <sup>
          th
         </sup>
         degree laceration or uterine rupture, soaking &gt;1 pad/hour, soaking 1 pad/hour for two consecutive hours, or passing a ≥6 cm clot).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The AWOHNN risk assessment tool is used by many facilities in the United States and is based upon the CMQCC tool.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         An
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2F-%2Fmedia%2Fproject%2Facog%2Facogorg%2Ffiles%2Fforms%2Fdistricts%2Fsmi-ob-hemorrhage-bundle-risk-assessment-ld-admin-intrapartum.pdf&amp;token=Mx4dCi6oa1zUVcSqr%2FsFgG7cSbaMvk4qdL2ie0y45rpjjgMdWVw%2Fu5f%2BUbkDM8qdIWhgvMp7F5ocNdbyeb4o8nBI2pW0yYJkF%2BXDTB10Exv4Rz4s4%2Ff8CA0kTG7EN%2BBS5HkRI3PfLyaTNEXjyOSFng%3D%3D&amp;TOPIC_ID=6710" target="_blank">
          online
         </a>
         tool created by the ACOG Safe Motherhood Initiative is similar.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The tool used at the author's institution  (
         <a class="graphic graphic_table graphicRef126216" href="/z/d/graphic/126216.html" rel="external">
          table 4
         </a>
         ) is also similar, but a disadvantage is that it does not include new risk factors developing over the course of labor and postpartum.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other tools are available on the UpToDate society guidelines links page for obstetric hemorrhage (see
         <a class="medical medical_society_guidelines" href="/z/d/html/118733.html" rel="external">
          "Society guideline links: Obstetric hemorrhage"
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H926619949">
         <span class="h2">
          Planning and intervention for selected groups of high-risk patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         [
         <a href="#rid5">
          5,44
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who decline to accept blood transfusion (see
         <a class="medical medical_review" href="/z/d/html/7927.html" rel="external">
          "Approach to the patient who declines blood transfusion"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with PAS (see
         <a class="medical medical_review" href="/z/d/html/6759.html" rel="external">
          "Placenta accreta spectrum: Clinical features, diagnosis, and potential consequences"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83129.html" rel="external">
          "Placenta accreta spectrum: Management"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with placenta previa (see
         <a class="medical medical_review" href="/z/d/html/6772.html" rel="external">
          "Placenta previa: Epidemiology, clinical features, diagnosis, morbidity and mortality"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6809.html" rel="external">
          "Placenta previa: Management"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with bleeding disorders (Von Willebrand disease [VWD], hemophilia, congenital factor XIII deficiency, unclassified bleeding disorder or bleeding disorder of unknown cause) (see
         <a class="medical medical_review" href="/z/d/html/94347.html" rel="external">
          "Perioperative blood management: Strategies to minimize transfusions"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Should all patients with PPH be screened for an inherited bleeding diathesis? – A prior PPH alone is not a strong indication for screening for inherited bleeding diatheses, given that undiagnosed bleeding disorders are a rare cause of PPH [
         <a href="#rid49">
          49
         </a>
         ]. However, unexplained PPH that does not respond to general measures should alert clinicians to the possibility of a bleeding disorder as a causative factor [
         <a href="#rid50">
          50
         </a>
         ], especially in patients with a history of heavy menstrual bleeding, excessive bleeding after minor trauma, or a family history of a bleeding disorder. (See
         <a class="medical medical_review" href="/z/d/html/1310.html" rel="external">
          "Clinical manifestations and diagnosis of hemophilia", section on 'Obstetric considerations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">
          "Use of anticoagulants during pregnancy and postpartum", section on 'Labor and delivery'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6681.html" rel="external">
          "Thrombocytopenia in pregnancy", section on 'Management decisions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139017.html" rel="external">
          "von Willebrand disease (VWD): Gynecologic and obstetric considerations", section on 'Obstetric considerations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with thrombocytopenia (see
         <a class="medical medical_review" href="/z/d/html/6681.html" rel="external">
          "Thrombocytopenia in pregnancy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with anemia (see
         <a class="medical medical_review" href="/z/d/html/115637.html" rel="external">
          "Anemia in pregnancy", section on 'Management'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H304367899">
         <span class="h2">
          Choice of birth facility for patients identified as high-risk prenatally
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients identified prenatally as high risk for PPH should plan to give birth at a facility that has an appropriate level of care for their needs. For example, a patient with PAS should plan for delivery at a facility where multidisciplinary expertise is available (maternal-fetal medicine, anesthesiology, interventional radiology, blood bank, surgery [general, vascular, urology], neonatology), whereas a patient with twins is less likely to need this level of care.
        </p>
        <p class="headingAnchor" id="H1493140717">
         <span class="h2">
          PPH management protocols
         </span>
         <span class="headingEndMark">
          —
         </span>
         Each hospital labor and delivery unit should have a PPH protocol and provide ongoing training to their staff regarding its use [
         <a href="#rid43">
          43,51-53
         </a>
         ]. The protocol should provide a standardized approach to evaluating and monitoring the patient with PPH, notifying a multidisciplinary team, and treatment. Development and consistent application of a comprehensive protocol for management of PPH appears to result in improved outcomes for these patients [
         <a href="#rid54">
          54-56
         </a>
         ]. In an observational study, initiating a PPH protocol was associated with resolution of maternal bleeding at an earlier stage, a 26 percent reduction in use of blood products, a 15 percent reduction in peripartum hysterectomy, and a 64 percent reduction in disseminated intravascular coagulation [
         <a href="#rid55">
          55,57
         </a>
         ].
        </p>
        <p>
         In the United States, The Joint Commission requires obstetric units to have written evidence-based procedures (developed by a multidisciplinary team) for stage-based management of pregnant and postpartum patients who experience hemorrhage, including [
         <a href="#rid43">
          43
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of an evidence-based tool that includes an algorithm for identification and treatment of hemorrhage
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of an evidence-based set of emergency response medication(s) that are immediately available on the obstetric unit
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A response team with a description of required team members and their roles in the event of severe hemorrhage
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A description of how the response team and procedures are activated
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood bank planning that includes emergency release of blood products and initiating massive transfusion
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Guidance on when to consult additional experts and consider transfer to a higher level of care
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Guidance on how to communicate with patients and families during and after the event
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Criteria for when a team debrief is required immediately after a case of severe hemorrhage
        </p>
        <p>
        </p>
        <p>
         The author's institution uses a checklist system that addresses some of these requirements  (
         <a class="graphic graphic_figure graphicRef126212" href="/z/d/graphic/126212.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         Resources for developing a PPH protocol include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cmqcc.org%2Fresources-tool-kits%2Ftoolkits%2Fob-hemorrhage-toolkit&amp;token=Fy7OONGXYS0fkPZpZMq%2B%2FT%2FfpTqt%2BPWZAdPlPf9WBSrYGkq0mZbCyT7ovL4gDJij9VdckOV520er6Oo2f51dc03FjSTEkUrfQ%2FWtHQlNRJE%3D&amp;TOPIC_ID=6710" target="_blank">
          California Maternal Quality Care Collaborative
         </a>
         (CMQCC), which provides comprehensive information in several formats for management of PPH [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medical society and government-sponsored guidelines, which can be found on the UpToDate society guidelines links page for obstetric hemorrhage (see
         <a class="medical medical_society_guidelines" href="/z/d/html/118733.html" rel="external">
          "Society guideline links: Obstetric hemorrhage"
         </a>
         ). There is large variation in obstetric and hematologic management of severe PPH across resource-abundant countries worldwide [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H676315320">
         <span class="h3">
          Massive transfusion protocol and algorithm
         </span>
         <span class="headingEndMark">
          —
         </span>
         Massive transfusion is required to support patients with massive hemorrhage and facilitated by use of protocols and algorithms  (
         <a class="graphic graphic_algorithm graphicRef91236" href="/z/d/graphic/91236.html" rel="external">
          algorithm 1
         </a>
         ) specific to the hospital. Massive transfusion has been defined as transfusion of ≥10 units of whole blood or red blood cells in 24 hours, ≥3 units of red blood cells in one hour, or ≥4 blood components in 30 minutes, recognizing that blood loss is a continuum and these are arbitrary cutoffs. (See
         <a class="medical medical_review" href="/z/d/html/7931.html" rel="external">
          "Massive blood transfusion"
         </a>
         .)
        </p>
        <p>
         All providers should be very familiar with application of their institution's protocol. Regular simulation of activation of PPH and massive transfusion protocols can improve compliance and facilitate team performance of low-frequency/high-complexity/high-risk events [
         <a href="#rid59">
          59,60
         </a>
         ]. (See
         <a class="local">
          'Training and simulation'
         </a>
         below.)
        </p>
        <p>
         The protocol should describe activation criteria, process of activation (phone or electronic), how blood products are provided, type and frequency of laboratory testing, when to transfuse, and criteria for termination of the protocol [
         <a href="#rid61">
          61
         </a>
         ]. It should include specific recommendations for empiric calcium replacement, potassium monitoring (hyperkalemia), and core body temperature management. Calcium is often necessary in severe PPH due to the citrate used for anticoagulation in blood products [
         <a href="#rid62">
          62
         </a>
         ]. During a massive transfusion, the obstetric anesthesiologist will often check ionized calcium in arterial blood gas specimens and will replete as necessary. In practice, a calcium infusion may be started empirically after two to three units of blood are transfused. Hypothermia must be prevented by warming fluids and blood products to be transfused, keeping the room warm, and covering the patient with warm blankets to the extent possible. (See
         <a class="medical medical_review" href="/z/d/html/94588.html" rel="external">
          "Perioperative temperature management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1606538924">
         <span class="h2">
          Equipment
         </span>
        </p>
        <p class="headingAnchor" id="H2102609916">
         <span class="h3">
          PPH carts/kits
         </span>
         <span class="headingEndMark">
          —
         </span>
         Planning for PPH involves ensuring availability of resources that might be needed, including personnel, uterotonic and other medications, equipment for control of bleeding, adequate intravenous access, topical hemostatic agents, and blood products. One way to achieve this is to assemble carts/kits that contain medications, devices, and instruments that may be needed to manage PPH so that these resources are readily available when needed (similar to a "code cart")  (
         <a class="graphic graphic_table graphicRef110293" href="/z/d/graphic/110293.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid5">
          5,60
         </a>
         ]. In the United States, The Joint Commission requires obstetric units to have a standardized, secured, dedicated hemorrhage supply kit stocked per the organization's defined process and, at a minimum, emergency hemorrhage supplies as determined by the organization and the organization's approved procedures for severe hemorrhage response [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4212503409">
         <span class="h3">
          Cell salvage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of a cell saver (blood salvage) is an option for patients undergoing cesarean birth at high risk of PPH. Routine use in all cesarean births is not cost-effective [
         <a href="#rid63">
          63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6712.html" rel="external">
          "Postpartum hemorrhage: Management approaches requiring laparotomy", section on 'Role of intraoperative cell salvage'
         </a>
         .)
        </p>
        <p>
         Cell salvage has been used successfully in patients with PPH after a vaginal birth, but data are sparse and the procedure should be considered investigational [
         <a href="#rid64">
          64
         </a>
         ]. The potential presence of blood contaminants, including stool, urine, cleansing agents (eg, betadine,
         <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">
          chlorhexidine
         </a>
         ), and vasoactive medications (eg,
         <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">
          misoprostol
         </a>
         ) is a contraindication, thus severely limiting use.
        </p>
        <p class="headingAnchor" id="H2813740485">
         <span class="h2">
          Personnel
         </span>
        </p>
        <p class="headingAnchor" id="H3395833543">
         <span class="h3">
          Multidisciplinary team
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the author's opinion, it is critical to appreciate that clinical training programs that encourage a team approach for early recognition of PPH can improve outcomes by engaging the spectrum of necessary providers before development of hypovolemia and uncompensated shock.
        </p>
        <p>
         Obstetricians, maternal-fetal medicine specialists, midwives, nurses, anesthesiologists, hematologists, blood bank personnel, laboratory medicine, general surgeons and surgical subspecialists (eg, vascular, urology, gynecologic oncology), and interventional radiologists may be involved in managing PPH. These individuals are often summoned and required to work together under conditions of great stress and time pressures. Coordination is essential and can be facilitated by protocols and flow diagrams that anticipate how the team will communicate and function together [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H449597476">
         <span class="h3">
          Training and simulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States, The Joint Commission recommends that obstetric staff [
         <a href="#rid43">
          43
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Undergo team training to teach staff to work together and communicate more effectively when PPH occurs
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conduct clinical drills to help staff prepare for PPH
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conduct debriefings after PPH to evaluate team performance and identify areas for improvement
        </p>
        <p>
        </p>
        <p>
         Simulation team training can help to identify areas that need practice, and regular unannounced simulated PPH scenarios in a real-life setting, such as the labor and delivery unit or post-anesthesia care unit, may also increase comfort with the protocols and teamwork required in such emergencies [
         <a href="#rid65">
          65
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4463.html" rel="external">
          "Reducing adverse obstetric outcomes through safety sciences", section on 'Postpartum hemorrhage'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3278350078">
         <span class="h3">
          Postevent review
         </span>
         <span class="headingEndMark">
          —
         </span>
         PPH cases that meet severity criteria established by the hospital should be reviewed to evaluate the effectiveness of the care, treatment, and services provided during the event [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H100823664">
         <span class="h1">
          EARLY RECOGNITION, ASSESSMENT, AND INTERVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ongoing risk assessment/close observation enables early recognition of excessive bleeding and prompt mobilization of the resources needed for an appropriate response  (
         <a class="graphic graphic_algorithm graphicRef141880" href="/z/d/graphic/141880.html" rel="external">
          algorithm 2
         </a>
         ). This principle applies globally and to high-, middle-, and low-resource countries.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A nationwide confidential enquiry of maternal deaths related to PPH in the Netherlands concluded that the key factors in preventing maternal death were [
         <a href="#rid66">
          66
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Early recognition of persistent bleeding
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prompt involvement of a senior clinician
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Early determination of the cause of bleeding
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Early assessment of severity of blood loss and presence of coagulopathy
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Timely intervention to control bleeding (including timely recourse to surgical interventions, including hysterectomy, when other management options fail to stop bleeding)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A randomized trial compared a multicomponent clinical intervention for PPH versus usual care in over 210,000 patients having a vaginal birth in 80 secondary-level hospitals across Kenya, Nigeria, South Africa, and Tanzania [
         <a href="#rid67">
          67
         </a>
         ]. The components included a calibrated blood-collection drape to quantify blood loss, a bundle of first-line treatments (uterine massage, uterotonic medications,
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         , intravenous fluids, examination [genital tract, placenta], and escalation of response when necessary), and an implementation strategy. The trial had a baseline observational phase (110,473 patients) followed by an implementation phase (99,659 patients).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the implementation phase, the intervention resulted in a 60 percent reduction in the primary composite outcome (blood loss ≥1000 mL, laparotomy for bleeding, or maternal death from bleeding: 1.6 versus 4.3 percent with usual care; risk ratio 0.40, 95% CI 0.32-0.50), which likely resulted from much better detection of PPH (93.1 versus 51.1 percent; rate ratio 1.58, 95% CI 1.41-1.76) coupled with high adherence to an evidence-based treatment bundle (91.2 versus 19.4 percent; rate ratio 4.94, 95% CI 3.88-6.28).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although these findings represent outcomes in a low-resource environment where nursing availability, expert consultant level clinicians, blood products, and access to surgical services are more limited than in high-resource countries, they validate the key principle that close observation (using a calibrated drape) and implementation of a bundle of actions in an incremental way is effective.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3686615128">
         <span class="h2">
          Quantify blood loss
         </span>
         <span class="headingEndMark">
          —
         </span>
         The term "estimated blood loss" (EBL) describes a qualitative approach to blood loss and the term "quantitative blood loss" (QBL) describes the systematic use of volumetric containers and weighing scales, or computerized image recognition, to quantify blood loss.
        </p>
        <p>
        </p>
        <p>
         We recommend QBL for all births because delay in the recognition of excessive blood loss delays timely initiation of life-saving interventions and is a common finding in cases of maternal morbidity and mortality from hemorrhage [
         <a href="#rid68">
          68-70
         </a>
         ]. Standardizing as many procedures as possible improves quality and safety; thus, if QBL is reserved only for cases of significant bleeding, staff may be unfamiliar with the process/procedures and less likely to obtain accurate data. With practice and routine adoption, QBL takes only minutes in most births [
         <a href="#rid5">
          5
         </a>
         ]. The Association of Women's Health, Obstetric and Neonatal Nurses (AWOHNN) recommends QBL and many anesthesiologists prefer QBL; however, the American College of Obstetricians and Gynecologists (ACOG) has not recommended QBL over EBL.
        </p>
        <p>
         QBL options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Volumetry
         </strong>
         – Collect blood in graduated measurement containers, such as V-drapes with calibrated pockets and calibrated suction canisters.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gravimetry
         </strong>
         – Measure the total weight of bloody materials and subtract the known weight of the same materials when dry. The difference in weight between wet and dry in grams approximates the volume of blood in milliliters.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Colorimetry with artificial intelligence
         </strong>
         – Use a smartphone application to calculate blood loss. The app analyzes photographs of used surgical gauze and canisters taken by the phone and then filters out the effects of nonblood components mixed into each sponge and canister. The hemoglobin mass present in the gauze or canister is then subtracted from the preoperative hemoglobin level. A meta-analysis found that this method correlated well with a validated reference, but more data are needed before it can be recommended for clinical use [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Visual aids
         </strong>
         – Use visual aids (eg, posters) that correlate the size and appearance of blood on specific surfaces (eg, maternity pad, bed sheet, lap sponge) with the volume of blood absorbed by that surface  (
         <a class="graphic graphic_picture graphicRef103418" href="/z/d/graphic/103418.html" rel="external">
          picture 1
         </a>
         ). Regularly scheduling standardized training in the use of these charts can be helpful. This approach is different from the traditional visual impression of EBL.
        </p>
        <p>
        </p>
        <p>
         For each of the above methods other than colorimetry, the clinician should attempt to account for fluids other than blood (eg, amniotic fluid, irrigation fluid, urine) that are collected or absorbed. A systematic review of two trials found insufficient evidence to support the use of two objective methods of QBL (volumetric measurement, gravimetry) over visual estimation of blood loss after vaginal birth or to support use of volumetric measurement over gravimetry [
         <a href="#rid72">
          72
         </a>
         ]. Although objective methods of QBL are more accurate (visual estimation is more likely to underestimate the actual blood loss when volumes are excessive and overestimate when volumes are normal), use of objective methods or a specific objective method of QBL did not clearly improve maternal and neonatal clinical outcomes. Additional appropriately powered, randomized trials that correlate method of estimating blood loss with relevant clinical outcomes are needed.
        </p>
        <p>
         Calculated blood loss (CBL) is sometimes used in retrospective and research studies. It is the peripartum hematocrit change (estimated blood volume × [(antepartum hematocrit–postpartum hematocrit)/antepartum hematocrit], where estimated blood volume [mL] = booking weight [kg] × 85). In a study that compared QBL and CBL in over 8000 patients, QBL and CBL were moderately correlated after vaginal birth, but QBL was less than CBL and the difference increased with increasing blood loss [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1290628907">
         <span class="h2">
          Recognize alarm findings and intervene early
         </span>
         <span class="headingEndMark">
          —
         </span>
         Timely recognition of PPH followed by rapid determination of the cause and initiation of appropriate treatment before the patient becomes moribund is critical to prevent death, as almost 90 percent of deaths due to PPH occur within four hours of giving birth [
         <a href="#rid74">
          74,75
         </a>
         ]. Early intervention by a multidisciplinary team led by an experienced clinician(s) may prevent shock and the development of the potentially lethal triad of hypothermia, acidosis, and coagulopathy. The types and choices of intervention depend, in part, on whether the birth was vaginal or cesarean (with the abdomen still open), and are described in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6712.html" rel="external">
          "Postpartum hemorrhage: Management approaches requiring laparotomy"
         </a>
         .)
        </p>
        <p>
         Alarm findings include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Early warning vital sign criteria
         </strong>
         – Standardized maternal early warning systems (MEWS) that target specific vital sign criteria  (
         <a class="graphic graphic_table graphicRef104186" href="/z/d/graphic/104186.html" rel="external">
          table 6
         </a>
         ) and mandate an immediate response at these thresholds can reduce maternal morbidity [
         <a href="#rid76">
          76,77
         </a>
         ]. However, the immediate response does not always occur: Several maternal mortality review committees have found that delayed response to abnormal vital signs is a common factor in preventable mortality [
         <a href="#rid78">
          78,79
         </a>
         ]. In some cases, the delay may be related to alarm fatigue because the trigger values used in the system have low specificity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         From a pragmatic perspective, it is wise to always assume, and rule out, PPH as the cause of symptoms of hypovolemia before assigning a less concerning diagnosis. It is important to recognize worrisome trends in vital signs because they may appear before early warning system criteria are met. A large reduction in blood pressure is a late sign of severe PPH as it is generally not manifested until substantial bleeding has occurred; up to 25 percent of a patient's blood volume (≥1500 mL in pregnancy) can be lost before systolic pressure falls to &lt;90 mmHg, heart rate rises above 120 beats/minute, and respiratory rate rises above 30 breaths/minute [
         <a href="#rid80">
          80
         </a>
         ]. This is the reason that blood loss ≥500 mL with continued bleeding for a vaginal birth and &gt;1000 mL with continued bleeding for a cesarean birth are considered alarm triggers [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A lack of excessive vaginal bleeding does not exclude the diagnosis since the possibility of concealed hemorrhage must always be considered. Pain unrelieved by standard pharmacotherapy can be associated with tachycardia and can be a sign of concealed hemorrhage. Although vasodilatation due to neuraxial anesthesia and vasovagal reactions may result in lightheadedness/syncope, tachycardia, and hypotension, these entities are less likely postpartum than PPH, and they are readily reversible and generally not dangerous. Lightheadedness, tachycardia, or hypotension is unlikely to be due to neuraxial anesthesia if the patient was hemodynamically stable prior to birth, the level of the block did not become significantly higher immediately following birth, and symptoms did not abruptly follow systemic administration of a drug known to cause hypotension. Although fever from infection is associated with tachycardia, the combination tachycardia and fever does not exclude the possibility of coexisting infection and concealed hemorrhage. (See
         <a class="medical medical_review" href="/z/d/html/4469.html" rel="external">
          "Adverse effects of neuraxial analgesia and anesthesia for obstetrics", section on 'Hypotension'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High shock index (SI)
         </strong>
         – SI is calculated by dividing the heart rate by the systolic blood pressure (ie, HR/SBP). The upper limit of normal in obstetric patients appears to be higher than in nonpregnant patients, and has been reported to be 0.9 to 1.1 [
         <a href="#rid81">
          81-85
         </a>
         ]. In a retrospective case-control study performed in a county safety net hospital, SI and delta-SI (ie, peak SI minus baseline SI) appeared to be superior to heart rate and systolic blood pressure in predicting PPH and the need for intervention (transfusion, surgery); SI &gt;1.14 and SI &gt;1.41 were strong "initial" and "critical" thresholds whereas SI ≤1.1 could be normal in peripartum individuals [
         <a href="#rid86">
          86
         </a>
         ]. SI remained sensitive and specific when adjusted for potential confounders, including maternal age, maternal weight, gestational age at delivery, prior parity, laboring on presentation, preeclampsia, chorioamnionitis, and mode of delivery. Delta-SI was the strongest classifier overall. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Initial patient assessment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Low fibrinogen
         </strong>
         – A fibrinogen level less than 200 mg/dL is an excellent predictor of severe PPH, defined as need for transfusion of multiple units of blood and blood products, need for angiographic embolization or surgical management of hemorrhage, or maternal death. It was the most frequently observed coagulation deficit in a cohort of patients with massive PPH, occurring in 17 percent of cases [
         <a href="#rid40">
          40
         </a>
         ]. For this reason, measuring the fibrinogen level as soon as PPH is suspected and keeping the level above 200 mg/dL in patients at high risk for, or experiencing, PPH is important. The author of this topic aims for a level &gt;300 mg/dL in patients with active bleeding where large amounts of blood products and crystalloid are often being transfused, given the higher normal baseline fibrinogen level in pregnancy and the desire to maintain the fibrinogen level well above the danger zone in these patients, although the benefit of increasing fibrinogen levels above 200 to 250 mg/dL in this setting has not been established.
        </p>
        <p>
        </p>
        <p>
         Hemoglobin and hematocrit values are poor indicators of acute blood loss since they may not decline immediately after an acute bleed. It can take four hours for changes in laboratory values to be seen, and the nadir may not be seen for 48 to 72 hours [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Laboratory evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3263160400">
         <span class="h2">
          Identify the cause of bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Physical examination to determine the cause of hemorrhage includes vaginal examination to look for vaginal and cervical lacerations and vaginal hematomas, abdominal examination to evaluate uterine tone and look for signs of intraabdominal hemorrhage, and possibly bimanual examination of the uterus.
        </p>
        <p>
         Ultrasound can be useful if the clinician suspects retained placental fragments or membranes or concealed hemorrhage (eg, lower uterine genital tract hematoma with extension, uterine rupture, broad ligament laceration, or another source of internal bleeding).
        </p>
        <p class="headingAnchor" id="H50579436">
         <span class="h2">
          Monitor bleeding, vital signs, and laboratory results and perform an examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Close maternal monitoring is critical to assess the best approach to and aggressiveness of intervention, and requires bedside evaluation by the provider.
        </p>
        <p>
         Laboratory evaluation may include, depending on the clinical scenario, (see
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Routine'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coagulation studies (fibrinogen level, prothrombin time [PT], activated partial thromboplastin time [aPTT])
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type and screen or crossmatch
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Potassium and ionized calcium levels
        </p>
        <p>
        </p>
        <p>
         In patients with major bleeding and coagulopathy, point-of-care viscoelastic testing provides nearly real-time data for guiding transfusion of blood products. Its use leads to better hemorrhage control, in part because of rapid detection and targeted treatment of hypofibrinogenemia and thrombocytopenia. This is a highly complex laboratory test, requiring a skilled technician, specialized equipment, and specialized reagents. It is often used in trauma, cardiac, and thoracic surgery during daytime hours when many resources are available. While data in nonpregnant patients suggest that viscoelastic tests may reduce mortality [
         <a href="#rid87">
          87
         </a>
         ], reduction in maternal mortality has not yet been demonstrated despite data showing that these tests reduce the need for transfusion of blood products and the rate of circulatory overload [
         <a href="#rid88">
          88,89
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Viscoelastic testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1159964769">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many potential interventions for treatment of PPH are available and listed in the table  (
         <a class="graphic graphic_table graphicRef73412" href="/z/d/graphic/73412.html" rel="external">
          table 7
         </a>
         ). Treatment goals and our approach to achieving these goals are described in the following sections.
        </p>
        <p class="headingAnchor" id="H2519343764">
         <span class="h2">
          Goals
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Restore or maintain adequate circulatory volume to prevent hypoperfusion of vital organs
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Restore or maintain adequate tissue oxygenation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reverse or prevent coagulopathy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eliminate the obstetric cause of PPH
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2488264461">
         <span class="h2">
          Initial approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial treatment approach is based on a combination of factors, including the cause and severity of bleeding and whether the abdomen is already open because of cesarean birth. The obstetric provider should initiate a sequence of nonoperative and operative interventions to control bleeding based on the cause and promptly assess the success of each measure. If an intervention fails, the next treatment in the sequence should be swiftly instituted. Indecisiveness delays therapy and results in excessive hemorrhage, which eventually causes dilutional coagulopathy and severe hypovolemia, tissue hypoxia, hypothermia, and acidosis. This will make control of hemorrhage much more difficult and will increase the likelihood of hysterectomy, major morbidity from hemorrhagic shock, and death.
        </p>
        <p>
         The following is a synopsis of the treatment approach for the four causes of PPH. Regardless of the cause, all patients should receive initial circulatory support with crystalloid. In those with severe bleeding, switching to blood transfusion when blood is available and early administration of
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         (an antifibrinolytic drug) can reduce the risk of death due to bleeding. These interventions are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Resuscitate with crystalloid and blood'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Transfuse red blood cells, platelets, plasma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Administer tranexamic acid'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atony
         </strong>
         – Treatment of atony, the most common cause of PPH, is influenced by both the route of birth and severity of bleeding. After a vaginal birth, treatment of atony begins with uterotonic drugs and minimally invasive procedures (eg, intrauterine devices such as a balloon for tamponade or low-level vacuum to facilitate uterine compressive forces ) and progresses to more invasive procedures (eg, uterine artery embolization or surgical intervention) until hemorrhage is controlled. Treatment of atony after vaginal birth (eg, choice of drugs, dosing) is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Manage atony'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Uterotonic medications are also used to treat atony at cesarean birth, but since the abdomen is already open, surgical procedures to control bleeding (eg, uterine artery and utero-ovarian artery ligation, uterine compression sutures) are employed much sooner than after a vaginal birth, and uterine artery embolization may be considered if these procedures fail. Hysterectomy is the definitive therapy when bleeding cannot be controlled by other measures within a timeframe appropriate for the clinical scenario. These procedures are described separately. (See
         <a class="medical medical_review" href="/z/d/html/6712.html" rel="external">
          "Postpartum hemorrhage: Management approaches requiring laparotomy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trauma
         </strong>
         – Traumatic, hemorrhaging lacerations are controlled surgically, either via a transvaginal or transabdominal approach, as appropriate for the site of bleeding. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Repair genital tract lacerations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6712.html" rel="external">
          "Postpartum hemorrhage: Management approaches requiring laparotomy", section on 'Myometrial lacerations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6712.html" rel="external">
          "Postpartum hemorrhage: Management approaches requiring laparotomy", section on 'Laceration of the uterine artery or utero-ovarian artery branches'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Retained placental tissue
         </strong>
         – Retained placental tissue can be identified visually and by palpation at a cesarean birth or by palpation after a vaginal birth. It can be removed manually or with use of instruments (eg, hemostat, Kelly, or curette). In cases of delayed (secondary) hemorrhage, retained placental tissue is usually detected by ultrasound and removed by curettage. (See
         <a class="medical medical_review" href="/z/d/html/15333.html" rel="external">
          "Retained placenta after vaginal birth"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Placenta accreta spectrum (PAS) generally requires hysterectomy, but uterine conservation with placental resection may be successful without excessive risk in selected cases of focal accreta or a posterior or fundal accreta. Diagnosis, preoperative planning, and management are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6759.html" rel="external">
          "Placenta accreta spectrum: Clinical features, diagnosis, and potential consequences"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83129.html" rel="external">
          "Placenta accreta spectrum: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coagulopathy
         </strong>
         – Coagulopathy is treated medically with transfusion of blood products and/or clotting factors to correct the clotting factor deficiencies. Treatment of coagulopathy is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Correct clotting factor deficiencies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1877271483">
         <span class="h2">
          Additional considerations for hemodynamically unstable patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to the initial approach to treatment described above, the following considerations apply to patients who are hemodynamically unstable.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Move the patient to an appropriate area
         </strong>
         – Unstable patients in a coagulopathic state with active bleeding should be managed in the most appropriate area for resuscitation and emergency surgery. Under most circumstances, this is a warm operating room with a full multidisciplinary team in attendance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transfuse as soon as possible
         </strong>
         – When hemorrhage is the cause of hemodynamic instability, initial (and expedited) aggressive volume resuscitation with whole blood or red cells and other appropriate blood products (eg, platelets, fresh frozen plasma, cryoprecipitate) is required (as opposed to large volume crystalloid infusion). Transfusion should keep up with blood loss and may require massive transfusion. In such cases, early activation of standardized institutional approach to massive transfusion can improve outcome. (See
         <a class="local">
          'Massive transfusion protocol and algorithm'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our approach to transfusion is described in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Transfuse red blood cells, platelets, plasma'
         </a>
         .).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Correct severe hypofibrinogenemia with high-concentration fibrinogen products
         </strong>
         – If the patient is severely coagulopathic with an extremely low fibrinogen level (50 to 100 mg/dL), cryoprecipitate and/or other high-concentration fibrinogen products (eg,
         <a class="drug drug_general" data-topicid="9082" href="/z/d/drug information/9082.html" rel="external">
          fibrinogen concentrate
         </a>
         ) are required since whole blood and fresh frozen plasma will not increase the fibrinogen level to the normal range (ideally greater than 200 mg/dL) without requiring excessive volume infusion. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Correct clotting factor deficiencies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7925.html" rel="external">
          "Plasma derivatives and recombinant DNA-produced coagulation factors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6712.html" rel="external">
          "Postpartum hemorrhage: Management approaches requiring laparotomy", section on 'Evaluation of the abdomen at laparotomy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Begin temporizing measures
         </strong>
         – Temporizing measures allow resuscitation to a point where general anesthesia and surgery, if necessary, are better tolerated. These interventions include bimanual uterine compression, intrauterine tamponade or vacuum device, aortic compression, and resuscitative endovascular balloon occlusion of the aorta (REBOA). (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Perform uterine massage and compression'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Consider external aortic compression'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Consider resuscitative endovascular balloon occlusion of the aorta'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Intrauterine tamponade can be performed with an intrauterine balloon  (
         <a class="graphic graphic_table graphicRef128495" href="/z/d/graphic/128495.html" rel="external">
          table 8
         </a>
         and
         <a class="graphic graphic_table graphicRef128496" href="/z/d/graphic/128496.html" rel="external">
          table 9
         </a>
         ), packing  (
         <a class="graphic graphic_table graphicRef128497" href="/z/d/graphic/128497.html" rel="external">
          table 10
         </a>
         ), or a low-level vacuum device that induces physiologic uterine contraction. The choice
         <strong>
         </strong>
         is largely driven by local availability, provider preference, and cost (see
         <a class="medical medical_review" href="/z/d/html/4440.html" rel="external">
          "Postpartum hemorrhage: Use of an intrauterine hemorrhage-control device"
         </a>
         ). The author believes early recourse to intrauterine tamponade can be useful to decrease ongoing uterine blood loss following vaginal birth or after the abdomen is closed following cesarean birth, and that this measure will allow additional time for assessment and evaluation, stabilization, and institution of resuscitative procedures. In some cases, intrauterine tamponade may avoid the need for surgical management of PPH [
         <a href="#rid90">
          90
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Use an intrauterine postpartum hemorrhage control device in patients with atony or lower segment bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients who continue to bleed at cesarean and still have an open abdominal incision, temporizing measures, compression sutures and devascularization are more easily accomplished than intrauterine tamponade. (See
         <a class="medical medical_review" href="/z/d/html/6712.html" rel="external">
          "Postpartum hemorrhage: Management approaches requiring laparotomy", section on 'Temporary measures for stabilizing hemodynamically unstable patients'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6712.html" rel="external">
          "Postpartum hemorrhage: Management approaches requiring laparotomy", section on 'Uterine compression sutures'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6712.html" rel="external">
          "Postpartum hemorrhage: Management approaches requiring laparotomy", section on 'Patients not at imminent risk of exsanguination'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of hysterectomy
         </strong>
         – Early resort to hysterectomy is appropriate in patients with severe bleeding due to diffuse PAS or a large uterine rupture, which require aggressive surgical management. In contrast, hysterectomy is generally not the first intervention in patients with atony, as these patients can often be managed successfully with medical therapy and less aggressive surgical interventions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In coagulopathic patients who require an emergency hysterectomy to control bleeding, concomitant blood product resuscitation during surgery is required. (See
         <a class="medical medical_review" href="/z/d/html/6712.html" rel="external">
          "Postpartum hemorrhage: Management approaches requiring laparotomy", section on 'Role of hysterectomy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Keep unstable patients with persistent bleeding in the operating room
         </strong>
         – If the abdomen was opened for management of PPH but bleeding was not completely controlled, temporarily closing the abdomen with towel clips enables the surgical team rapid direct access to the pelvis to repack or readdress ongoing bleeding (eg, digital pressure or a temporary clamp applied to the aorta).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The author is aware of situations where unstable, actively bleeding patients in a coagulopathic state have had their abdomen packed and then were transported to an intensive care unit (ICU), where they expired. In the author's opinion, in these desperate situations, keeping the patient under anesthesia on a surgical table in a warm environment gives the team the most options for gaining control of the situation (eg, acid-base resuscitation; replacement of volume, electrolytes, and blood products), even if logistically difficult. ICU consultants can be summoned to the operating room for assistance. Even in the direst situations, as long as transfusion of appropriate blood products can be continued and the volume of such products exceeds the volume of the ongoing loss, then blood pressure can be maintained and efforts to reverse the coagulopathy, acidosis, and hypothermia may ultimately be successful and should be continued.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3132821073">
         <span class="h2">
          Hemodynamically stable patients with persistent bleeding after initial therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Arterial embolization is an effective treatment for hemodynamically stable patients with persistent bleeding in whom the capacity for blood replacement exceeds that of the ongoing hemorrhage. In a systematic review of 20 observational studies (1739 patients), a single procedure completely arrested bleeding in 89 percent of cases, re-embolization was necessary in 4 percent, and hysterectomy was required in 7 percent, primarily after embolization failure [
         <a href="#rid91">
          91
         </a>
         ]. Sixty-two percent of the patients in these studies were post cesarean birth.
        </p>
        <p>
         Generally, arterial embolization should not be attempted in unstable patients who have to be transferred to a radiology suite for the procedure and should not be considered an emergency procedure for managing uncontrolled PPH of indeterminate cause. (See
         <a class="medical medical_review" href="/z/d/html/6712.html" rel="external">
          "Postpartum hemorrhage: Management approaches requiring laparotomy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Consider uterine or hypogastric artery embolization'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1552801591">
         <span class="h2">
          Role of nonpneumatic anti-shock garments
         </span>
         <span class="headingEndMark">
          —
         </span>
         In ambulances and facilities where definitive treatment of PPH is not possible or will be delayed because of lack of resources, use of a nonpneumatic anti-shock garment (NASG) may reduce bleeding, stabilize patients until they are transferred to an appropriate referral/tertiary facility, and decrease mortality from hypovolemic shock [
         <a href="#rid92">
          92-96
         </a>
         ]. With minimal training, NASG can be applied within two minutes and is reusable.
        </p>
        <p>
         NASG consists of nine articulated segments that are wrapped tightly and sequentially around the legs, pelvis, and abdomen and then closed with hook-and loop-fastening straps. Application of circumferential counterpressure decreases blood flow to the compressed area (abdominal aorta, pelvis, and lower extremities) and increases blood flow to the heart, lungs, and brain [
         <a href="#rid97">
          97
         </a>
         ]. The addition of a small foam ball centrally provides some degree of aortic as well as uterine compression and blood flow to the pelvis is reduced [
         <a href="#rid97">
          97,98
         </a>
         ]. Intrauterine tamponade can also be employed.
        </p>
        <p>
         In an analysis of five observational studies, NASG use was associated with a ≥50 percent reduction in median blood loss in three of four studies and a smaller reduction in one study [
         <a href="#rid92">
          92
         </a>
         ]. The analysis also found total pooled mortality was reduced 38 percent across the five studies, even though mortality was increased in one study.
        </p>
        <p class="headingAnchor" id="H4179130621">
         <span class="h2">
          Thromboprophylaxis after transfusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         The postpartum state is a risk factor for developing venous thromboembolism (VTE), especially in patients with tissue trauma and/or transfusion [
         <a href="#rid99">
          99-101
         </a>
         ]. For these reasons, for all patients who have been transfused for PPH:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initiate mechanical thromboprophylaxis (graduated compression stockings or a pneumatic compression device) as soon as feasible and continue thromboprophylaxis until discharge [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Add pharmacologic thromboprophylaxis 12 to 24 hours after bleeding has been controlled and coagulation tests are normal or close to normal. (See
         <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">
          "Use of anticoagulants during pregnancy and postpartum"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H100823827">
         <span class="h1">
          OUTCOME
         </span>
        </p>
        <p class="headingAnchor" id="H1874345430">
         <span class="h2">
          Mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maternal mortality after PPH has wide variations worldwide depending on both the overall health of the pregnant population and the resources for treatment of PPH [
         <a href="#rid103">
          103
         </a>
         ]. Death rates vary from 0.01 percent of patients with PPH in the United Kingdom to 20 percent of patients with PPH in parts of Africa, and from 1 in 100,000 births in the United Kingdom to 1 in 1000 births in resource-limited regions. Patients with anemia due to poor nutrition or malaria are particularly vulnerable to severe sequelae of PPH.
        </p>
        <p class="headingAnchor" id="H4025107351">
         <span class="h2">
          Severe maternal morbidity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severe maternal morbidity (ie, health-impacting and life-threatening events that occur during hospitalization for childbirth) has increased substantially in recent years, largely driven by an increase in blood transfusion for PPH  (
         <a class="graphic graphic_figure graphicRef127364" href="/z/d/graphic/127364.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/127359.html" rel="external">
          "Severe maternal morbidity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3503839425">
         <span class="h2">
          Short-term morbidity
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anemia
         </strong>
         – Postpartum anemia is common and usually defined as a hemoglobin level &lt;11 g/dL at one week postpartum and &lt;12 g/dL at eight weeks postpartum [
         <a href="#rid104">
          104
         </a>
         ]. Patients with PPH often have a 10-point decline in postpartum hematocrit from antepartum levels. The type of treatment depends on severity of anemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         One or more red cell transfusions may be required, depending on the severity of anemia and the degree of symptomatology attributable to anemia. A common practice is to offer a transfusion to symptomatic patients with a hemoglobin value &lt;7 g/dL [
         <a href="#rid4">
          4
         </a>
         ]. In the WOMAN trial, which included over 20,000 patients worldwide with PPH, 54 percent had transfusion. By comparison, in the United States the frequency of transfusion in births with PPH has been reported to be 16 percent [
         <a href="#rid36">
          36
         </a>
         ] and the frequency of transfusion in the overall obstetric population has been reported to be 4 to 7 per 1000 births [
         <a href="#rid105">
          105
         </a>
         ]. Risks of transfusion include infection, electrolyte abnormalities, allergic reactions, alloimmunization, volume overload, and venous thromboembolism (VTE). (See
         <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">
          "Indications and hemoglobin thresholds for RBC transfusion in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In most cases of PPH, iron supplementation is required because the amount of iron lost is not fully replaced by any transfused blood. Oral supplements are one option and single-dose parenteral iron therapy is another option. Advantages of parenteral iron are that hemoglobin levels rise faster, symptoms of anemia improve sooner, and less gastric upset occurs compared with oral therapy [
         <a href="#rid106">
          106,107
         </a>
         ]. Nevertheless, most patients with mild to moderate anemia resolve the anemia sufficiently rapidly with oral iron, and it is inexpensive and convenient [
         <a href="#rid108">
          108-110
         </a>
         ]. Assessment and treatment of iron deficiency anemia is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">
          "Treatment of iron deficiency anemia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although erythropoietin can increase the rate of recovery to normal hemoglobin levels, it does not have an immediate effect and has not been proven to reduce transfusion requirements after PPH [
         <a href="#rid111">
          111
         </a>
         ]. It is no more effective than iron therapy in this setting [
         <a href="#rid112">
          112
         </a>
         ], and it is expensive. However, for the few patients with severe anemia who do not respond to iron therapy because of blunted erythropoiesis due to infection and/or inflammation, some hematologists consider recombinant human erythropoietin an alternative to transfusion [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hysterectomy
         </strong>
         – In the WOMAN trial, 3.5 percent of patients with PPH underwent hysterectomy [
         <a href="#rid113">
          113
         </a>
         ]. By comparison, in the United States, 2.1 percent of patients with PPH underwent hysterectomy in 2014, and atony accounted for almost 60 percent of these cases [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Organ failure related to hemodynamic instability
         </strong>
         – In the WOMAN trial, 60 percent of patients with PPH had clinical signs of hemodynamic instability at diagnosis of PPH and almost 4 percent developed kidney failure, heart failure, respiratory failure, or hepatic failure [
         <a href="#rid113">
          113
         </a>
         ]. One mechanism is that treatment of hemodynamic instability with fluids and blood can lead to volume overload, resulting in pulmonary edema and dilutional coagulopathy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thromboembolism
         </strong>
         – In the WOMAN trial, 0.3 percent of patients with PPH experienced thromboembolism (deep vein thrombosis, pulmonary embolus, stroke, myocardial infarction) within 42 days of birth [
         <a href="#rid113">
          113
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abdominal compartment syndrome
         </strong>
         – Abdominal compartment syndrome (organ dysfunction caused by intraabdominal hypertension) is a rare but life-threatening complication of PPH with intraabdominal bleeding. The diagnosis should be considered in patients with a tensely distended abdomen and progressive oliguria who are developing multiorgan failure. Of note, the normal postpartum patient after cesarean birth has been reported to have an intraabdominal pressure that approaches that seen in abdominal compartment syndrome in nonpregnant individuals [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical presentation, diagnosis, and management are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2889.html" rel="external">
          "Abdominal compartment syndrome in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2532061075">
         <span class="h2">
          Long-term morbidity
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sheehan syndrome
         </strong>
         – Sheehan syndrome (ie, postpartum hypopituitarism) is a rare but potentially life-threatening complication. The pituitary gland is enlarged in pregnancy and prone to infarction from hypovolemic shock. The resulting pituitary damage ranges from mild to severe, and can reduce secretion of one, several, or all of its hormones. A common presentation is a combination of failure to lactate postpartum and amenorrhea or oligomenorrhea, but any of the manifestations of hypopituitarism (eg, hypotension, hyponatremia, hypothyroidism) can occur any time from the immediate postpartum period to years after birth.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who remain hypotensive after control of PPH and volume replacement should be evaluated and treated for adrenal insufficiency in the immediate postpartum period, whereas evaluation of other hormonal deficiencies can be deferred until four to six weeks postpartum. This evaluation is described in detail separately (see
         <a class="medical medical_review" href="/z/d/html/6637.html" rel="external">
          "Clinical manifestations of hypopituitarism"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6639.html" rel="external">
          "Diagnostic testing for hypopituitarism"
         </a>
         ). Treatment is also reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6640.html" rel="external">
          "Treatment of hypopituitarism"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asherman syndrome
         </strong>
         – Development of intrauterine adhesions (termed Asherman syndrome) can lead to menstrual abnormalities and infertility. Approximately 90 percent of cases of severe intrauterine adhesive disease are related to uterine curettage for pregnancy complications, such as PPH [
         <a href="#rid115">
          115,116
         </a>
         ]. Uterine compression sutures used to treat PPH have also been associated with the development of intrauterine adhesions [
         <a href="#rid117">
          117-120
         </a>
         ]. Diagnosis and treatment are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3285.html" rel="external">
          "Intrauterine adhesions: Clinical manifestation and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114037.html" rel="external">
          "Intrauterine adhesions: Treatment and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2499062005">
         <span class="h1">
          POSTPARTUM CARE
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Active management of the third stage of labor, primarily by routine prophylactic use of uterotonic drugs such as
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         , substantially reduces the incidence of PPH due to atony. While evidence is lacking regarding the optimal approach specifically in patients who have experienced PPH, it seems reasonable to prolong the duration of postpartum oxytocin administration when the cause was atony. Drug choice, dosing, and efficacy are described separately. (See
         <a class="medical medical_review" href="/z/d/html/4437.html" rel="external">
          "Management of the third stage of labor: Prophylactic pharmacotherapy to minimize hemorrhage"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PPH is a traumatic experience for patients that can have both short-term and long-term impacts on their mental health [
         <a href="#rid121">
          121-125
         </a>
         ]. Helping patients process and understand the events that occurred, discussing their concerns and prognosis, connecting them with a patient resource person, and referring them to emotional support and counseling services can mitigate the impact.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Before discharge, patients should be given information about normal bleeding, signs and symptoms associated with excessive bleeding, and when to call the provider, in addition to usual information about postpartum recovery. (See
         <a class="medical medical_review" href="/z/d/html/6711.html" rel="external">
          "Overview of the postpartum period: Normal physiology and routine maternal care", section on 'Patient education'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H512233917">
         <span class="h1">
          RECURRENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with a prior PPH have as much as an 18 percent risk of recurrence in the subsequent pregnancy and 27 percent after two consecutive pregnancies with PPH [
         <a href="#rid126">
          126-128
         </a>
         ]. The risk of recurrence likely depends, at least in part, on the underlying cause. In a study of patients with PPH from atony, lacerations, or retained placenta, the risks of atony and retained placenta remained increased in the next two pregnancies with vaginal births, whereas the risk of lacerations went down [
         <a href="#rid126">
          126
         </a>
         ]. Although the risk of recurrence was greatest for PPH from the same cause, the risk was also increased for PPH from other causes.
        </p>
        <p class="headingAnchor" id="H1169136010">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118733.html" rel="external">
          "Society guideline links: Obstetric hemorrhage"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H118359270">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/83068.html" rel="external">
          "Patient education: Postpartum hemorrhage (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis and assessment of severity
         </strong>
         – Primary (early) postpartum hemorrhage (PPH) refers to excessive bleeding in the first 24 hours after birth (see
         <a class="local">
          'Terminology'
         </a>
         above). We make the diagnosis in postpartum patients with:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bleeding that is greater than expected using a quantitative method to assess blood loss
         <strong>
          and
         </strong>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Results in signs and/or symptoms of hypovolemia  (
         <a class="graphic graphic_table graphicRef56885" href="/z/d/graphic/56885.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other definitions are shown in the table  (
         <a class="graphic graphic_table graphicRef113123" href="/z/d/graphic/113123.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Criteria for diagnosis'
         </a>
         above and
         <a class="local">
          'Quantify blood loss'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Severe PPH, defined as the need for transfusion of multiple units of blood and blood products, the need for angiographic embolization or surgical management of hemorrhage, or maternal death can be predicted by maternal early warning systems (MEWS) vital sign criteria  (
         <a class="graphic graphic_table graphicRef104186" href="/z/d/graphic/104186.html" rel="external">
          table 6
         </a>
         ) and by a low fibrinogen level (less than 200 mg/dL). (See
         <a class="local">
          'Recognize alarm findings and intervene early'
         </a>
         above and
         <a class="local">
          'Monitor bleeding, vital signs, and laboratory results and perform an examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Causes
         </strong>
         – The most common causes are atony, trauma, placental disorders, and coagulopathy/bleeding diatheses. (See
         <a class="local">
          'Causes of postpartum hemorrhage'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General approach algorithm
         </strong>
         (
         <a class="graphic graphic_algorithm graphicRef141880" href="/z/d/graphic/141880.html" rel="external">
          algorithm 2
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Planning
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Risk assessment
         </strong>
         – Patients with risk factors for PPH should be identified  (
         <a class="graphic graphic_table graphicRef126216" href="/z/d/graphic/126216.html" rel="external">
          table 4
         </a>
         ), when possible, and counseled as appropriate for their level of risk. However, only a small proportion of these patients develop PPH (abnormal placentation is an exception), and many patients without risk factors experience PPH. (See
         <a class="local">
          'Risk factors for PPH'
         </a>
         above and
         <a class="local">
          'PPH risk assessment tools and risk-based preparation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         PPH alone is not a strong indication for screening for inherited bleeding diatheses, given that undiagnosed bleeding disorders are rarely the cause of PPH. However, unexplained PPH that does not respond to general measures should alert clinicians to the possibility of a bleeding disorder as a causative factor, especially in patients with a history of heavy menstrual bleeding, excessive bleeding after minor trauma, or a family history of a bleeding disorder. (See
         <a class="local">
          'Recurrence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Preparation
         </strong>
         – Planning for PPH involves:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Quantifying blood loss in all births
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Ensuring availability of resources that might be needed (personnel, medications, equipment [eg, intrauterine tamponade, cell salvage], adequate intravenous access [eg, two large-bore cannulas], blood products).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Two useful approaches are PPH carts  (
         <a class="graphic graphic_table graphicRef110293" href="/z/d/graphic/110293.html" rel="external">
          table 5
         </a>
         ) and protocols to manage PPH (eg, massive transfusion protocol  (
         <a class="graphic graphic_algorithm graphicRef91236" href="/z/d/graphic/91236.html" rel="external">
          algorithm 1
         </a>
         )). Regular training and simulation drills should be instituted to ensure compliance, emergency stage-based response, and unit preparedness. (See
         <a class="local">
          'Institutional planning and preparation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          All patients
         </strong>
         – The initial treatment approach is based on a combination of factors, including the cause and severity of bleeding. (See
         <a class="local">
          'Goals'
         </a>
         above and
         <a class="local">
          'Initial approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Atony is initially treated with uterotonic drugs. Second-line treatment depends on the route of birth, as the morbidity of open operative interventions is less at cesarean since the abdomen is already open.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Lacerations are treated surgically.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Coagulopathy is treated with infusion of blood products and/or concentrates.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Regardless of the cause of PPH, initial circulatory support with crystalloid is required in all patients. In those with severe bleeding, switching to blood transfusion when blood is available and early administration of
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         reduces the risk of death due to bleeding. (See
         <a class="local">
          'Initial approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hemodynamically unstable patients
         </strong>
         – Key considerations in patients who are hemodynamically unstable include (see
         <a class="local">
          'Additional considerations for hemodynamically unstable patients'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Initial management in the most appropriate area for resuscitation and emergency surgery
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Transfusion as soon as possible
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Correction of severe hypofibrinogenemia with cryoprecipitate and/or other high-concentration fibrinogen products (eg,
         <a class="drug drug_general" data-topicid="9082" href="/z/d/drug information/9082.html" rel="external">
          fibrinogen concentrate
         </a>
         )
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Use of temporizing measures to allow resuscitation to a point where general anesthesia and surgery, if necessary, are better tolerated
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Early resort to hysterectomy
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Ongoing management of unstable patients with persistent bleeding in an operating room rather than an intensive care unit (ICU).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcome
         </strong>
         – PPH is associated with potentially serious short-term morbidities from hemorrhage and hypotension, and may be lethal. Potential long-term morbidities include Sheehan syndrome (in patients with hypotension) and Asherman syndrome (in patients who were curetted). (See
         <a class="local">
          'Outcome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H821896214">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Allan J Jacobs, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Jin XH, Li D, Li X. Carbetocin vs oxytocin for prevention of postpartum hemorrhage after vaginal delivery: A meta-analysis. Medicine (Baltimore) 2019; 98:e17911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sentilhes L, Sénat MV, Le Lous M, et al. Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery. N Engl J Med 2021; 384:1623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anger H, Durocher J, Dabash R, Winikoff B. How well do postpartum blood loss and common definitions of postpartum hemorrhage correlate with postpartum anemia and fall in hemoglobin? PLoS One 2019; 14:e0221216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 183: Postpartum Hemorrhage. Obstet Gynecol 2017; 130:e168. Reaffirmed 2023.
          </a>
         </li>
         <li class="breakAll">
          Lagrew D, McNulty J, Sakowski C, Cape V, McCormick E, Morton CH. Improving Health Care Response to Obstetric Hemorrhage, a California Maternal Quality Care Collaborative Toolkit, 2022.
         </li>
         <li class="breakAll">
          American College of Surgeons. Advanced Trauma Life Support (Student Manual). American College of Surgeons 1997.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheldon WR, Blum J, Vogel JP, et al. Postpartum haemorrhage management, risks, and maternal outcomes: findings from the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG 2014; 121 Suppl 1:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li S, Gao J, Liu J, et al. Incidence and Risk Factors of Postpartum Hemorrhage in China: A Multicenter Retrospective Study. Front Med (Lausanne) 2021; 8:673500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corbetta-Rastelli CM, Friedman AM, Sobhani NC, et al. Postpartum Hemorrhage Trends and Outcomes in the United States, 2000-2019. Obstet Gynecol 2023; 141:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deneux-Tharaux C, Bonnet MP, Tort J. [Epidemiology of post-partum haemorrhage]. J Gynecol Obstet Biol Reprod (Paris) 2014; 43:936.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmadzia HK, Grotegut CA, James AH. A national update on rates of postpartum haemorrhage and related interventions. Blood Transfus 2020; 18:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okunlola O, Raza S, Osasan S, et al. Race/Ethnicity as a Risk Factor in the Development of Postpartum Hemorrhage: A Thorough Systematic Review of Disparity in the Relationship Between Pregnancy and the Rate of Postpartum Hemorrhage. Cureus 2022; 14:e26460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lockwood CJ, Schatz F. A biological model for the regulation of peri-implantational hemostasis and menstruation. J Soc Gynecol Investig 1996; 3:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lockwood CJ, Nemerson Y, Krikun G, et al. Steroid-modulated stromal cell tissue factor expression: a model for the regulation of endometrial hemostasis and menstruation. J Clin Endocrinol Metab 1993; 77:1014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lockwood CJ. Regulation of plasminogen activator inhibitor 1 expression by interaction of epidermal growth factor with progestin during decidualization of human endometrial stromal cells. Am J Obstet Gynecol 2001; 184:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lockwood CJ, Krikun G, Schatz F. The decidua regulates hemostasis in human endometrium. Semin Reprod Endocrinol 1999; 17:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bateman BT, Berman MF, Riley LE, Leffert LR. The epidemiology of postpartum hemorrhage in a large, nationwide sample of deliveries. Anesth Analg 2010; 110:1368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rouse DJ, Leindecker S, Landon M, et al. The MFMU Cesarean Registry: uterine atony after primary cesarean delivery. Am J Obstet Gynecol 2005; 193:1056.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng YW, Delaney SS, Hopkins LM, Caughey AB. The association between the length of first stage of labor, mode of delivery, and perinatal outcomes in women undergoing induction of labor. Am J Obstet Gynecol 2009; 201:477.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blomberg M. Maternal obesity and risk of postpartum hemorrhage. Obstet Gynecol 2011; 118:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wetta LA, Szychowski JM, Seals S, et al. Risk factors for uterine atony/postpartum hemorrhage requiring treatment after vaginal delivery. Am J Obstet Gynecol 2013; 209:51.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer MS, Berg C, Abenhaim H, et al. Incidence, risk factors, and temporal trends in severe postpartum hemorrhage. Am J Obstet Gynecol 2013; 209:449.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharp GC, Saunders PT, Greene SA, et al. Intergenerational transmission of postpartum hemorrhage risk: analysis of 2 Scottish birth cohorts. Am J Obstet Gynecol 2014; 211:51.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruning AH, Heller HM, Kieviet N, et al. Antidepressants during pregnancy and postpartum hemorrhage: a systematic review. Eur J Obstet Gynecol Reprod Biol 2015; 189:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oberg AS, Hernandéz-Diaź S, Frisell T, et al. Genetic contribution to postpartum haemorrhage in Swedish population: cohort study of 466,686 births. BMJ 2014; 349:g4984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giannella L, Mfuta K, Pedroni D, et al. Delays in the delivery room of a primary maternity unit: a retrospective analysis of obstetric outcomes. J Matern Fetal Neonatal Med 2013; 26:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grzeskowiak LE, McBain R, Dekker GA, Clifton VL. Antidepressant use in late gestation and risk of postpartum haemorrhage: a retrospective cohort study. BJOG 2016; 123:1929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nyfløt LT, Sandven I, Oldereid NB, et al. Assisted reproductive technology and severe postpartum haemorrhage: a case-control study. BJOG 2017; 124:1198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nyfløt LT, Sandven I, Stray-Pedersen B, et al. Risk factors for severe postpartum hemorrhage: a case-control study. BMC Pregnancy Childbirth 2017; 17:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skalkidou A, Sundström-Poromaa I, Wikman A, et al. SSRI use during pregnancy and risk for postpartum haemorrhage: a national register-based cohort study in Sweden. BJOG 2020; 127:1366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butwick AJ, Liu C, Guo N, et al. Association of Gestational Age with Postpartum Hemorrhage: An International Cohort Study. Anesthesiology 2021; 134:874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linde LE, Ebbing C, Moster D, et al. Recurrence of postpartum hemorrhage in relatives: A population-based cohort study. Acta Obstet Gynecol Scand 2021; 100:2278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheiner E, Sarid L, Levy A, et al. Obstetric risk factors and outcome of pregnancies complicated with early postpartum hemorrhage: a population-based study. J Matern Fetal Neonatal Med 2005; 18:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mhyre JM, Shilkrut A, Kuklina EV, et al. Massive blood transfusion during hospitalization for delivery in New York State, 1998-2007. Obstet Gynecol 2013; 122:1288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evensen A, Anderson JM, Fontaine P. Postpartum Hemorrhage: Prevention and Treatment. Am Fam Physician 2017; 95:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reale SC, Easter SR, Xu X, et al. Trends in Postpartum Hemorrhage in the United States From 2010 to 2014. Anesth Analg 2020; 130:e119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Akker T, Brobbel C, Dekkers OM, Bloemenkamp KWM. Prevalence, Indications, Risk Indicators, and Outcomes of Emergency Peripartum Hysterectomy Worldwide: A Systematic Review and Meta-analysis. Obstet Gynecol 2016; 128:1281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ende HB, Lozada MJ, Chestnut DH, et al. Risk Factors for Atonic Postpartum Hemorrhage: A Systematic Review and Meta-analysis. Obstet Gynecol 2021; 137:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conrad LB, Groome LJ, Black DR. Management of Persistent Postpartum Hemorrhage Caused by Inner Myometrial Lacerations. Obstet Gynecol 2015; 126:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bell SF, Collis RE, Bailey C, et al. The incidence, aetiology, and coagulation management of massive postpartum haemorrhage: a two-year national prospective cohort study. Int J Obstet Anesth 2021; 47:102983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pergialiotis V, Bellos I, Fanaki M, et al. Risk factors for severe perineal trauma during childbirth: An updated meta-analysis. Eur J Obstet Gynecol Reprod Biol 2020; 247:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karavani G, Chill HH, Reuveni-Salzman A, et al. Risk factors for uterine incision extension during cesarean delivery. J Matern Fetal Neonatal Med 2022; 35:2156.
          </a>
         </li>
         <li class="breakAll">
          Joint Commission. Proposed Standards for Perinatal Safety Hospital (HAP) Accreditation Program https://jointcommission.az1.qualtrics.com/CP/File.php?F=F_2bMhcokkpaksMvz (Accessed on June 11, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dilla AJ, Waters JH, Yazer MH. Clinical validation of risk stratification criteria for peripartum hemorrhage. Obstet Gynecol 2013; 122:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawakita T, Mokhtari N, Huang JC, Landy HJ. Evaluation of Risk-Assessment Tools for Severe Postpartum Hemorrhage in Women Undergoing Cesarean Delivery. Obstet Gynecol 2019; 134:1308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Movva VC, Bringman J, Young A, et al. Comparison of three antepartum risk assessment tools to predict significant postpartum hemorrhage in livebirths. Transfusion 2023; 63:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neary C, Naheed S, McLernon DJ, Black M. Predicting risk of postpartum haemorrhage: a systematic review. BJOG 2021; 128:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carr BL, Jahangirifar M, Nicholson AE, et al. Predicting postpartum haemorrhage: A systematic review of prognostic models. Aust N Z J Obstet Gynaecol 2022; 62:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kadir RA, Kingman CE, Chi C, et al. Is primary postpartum haemorrhage a good predictor of inherited bleeding disorders? Haemophilia 2007; 13:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kadir RA, Aledort LM. Obstetrical and gynaecological bleeding: a common presenting symptom. Clin Lab Haematol 2000; 22 Suppl 1:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark SL, Frye DR, Meyers JA, et al. Reduction in elective delivery at &lt;39 weeks of gestation: comparative effectiveness of 3 approaches to change and the impact on neonatal intensive care admission and stillbirth. Am J Obstet Gynecol 2010; 203:449.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bailit JL, Grobman WA, McGee P, et al. Does the presence of a condition-specific obstetric protocol lead to detectable improvements in pregnancy outcomes? Am J Obstet Gynecol 2015; 213:86.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grobman WA, Bailit JL, Rice MM, et al. Can differences in obstetric outcomes be explained by differences in the care provided? The MFMU Network APEX study. Am J Obstet Gynecol 2014; 211:147.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizvi F, Mackey R, Barrett T, et al. Successful reduction of massive postpartum haemorrhage by use of guidelines and staff education. BJOG 2004; 111:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields LE, Wiesner S, Fulton J, Pelletreau B. Comprehensive maternal hemorrhage protocols reduce the use of blood products and improve patient safety. Am J Obstet Gynecol 2015; 212:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skupski DW, Brady D, Lowenwirt IP, et al. Improvement in Outcomes of Major Obstetric Hemorrhage Through Systematic Change. Obstet Gynecol 2017; 130:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields LE, Smalarz K, Reffigee L, et al. Comprehensive maternal hemorrhage protocols improve patient safety and reduce utilization of blood products. Am J Obstet Gynecol 2011; 205:368.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCall SJ, Henriquez D, Edwards HM, et al. A total blood volume or more transfused during pregnancy or after childbirth: Individual patient data from six international population-based observational studies. PLoS One 2021; 16:e0244933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Margarido C, Ferns J, Chin V, et al. Massive hemorrhage protocol activation in obstetrics: a 5-year quality performance review. Int J Obstet Anesth 2019; 38:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muñoz M, Stensballe J, Ducloy-Bouthors AS, et al. Patient blood management in obstetrics: prevention and treatment of postpartum haemorrhage. A NATA consensus statement. Blood Transfus 2019; 17:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Callum J, Evans CCD, Barkun A, Karkouti K. Nonsurgical management of major hemorrhage. CMAJ 2023; 195:E773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erfani H, Fox KA, Belfort MA, Shamshirsaz AA. Preventing severe hypocalcemia during surgery for placenta accreta spectrum. Acta Obstet Gynecol Scand 2019; 98:1358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim G, Melnyk V, Facco FL, et al. Cost-effectiveness Analysis of Intraoperative Cell Salvage for Obstetric Hemorrhage. Anesthesiology 2018; 128:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips JM, Sakamoto S, Buffie A, et al. How do I perform cell salvage during vaginal obstetric hemorrhage? Transfusion 2022; 62:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dillon SJ, Kleinmann W, Fomina Y, et al. Does simulation improve clinical performance in management of postpartum hemorrhage? Am J Obstet Gynecol 2021; 225:435.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramler PI, Beenakkers ICM, Bloemenkamp KWM, et al. Nationwide confidential enquiries into maternal deaths because of obstetric hemorrhage in the Netherlands between 2006 and 2019. Acta Obstet Gynecol Scand 2022; 101:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallos I, Devall A, Martin J, et al. Randomized Trial of Early Detection and Treatment of Postpartum Hemorrhage. N Engl J Med 2023; 389:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schorn MN. Measurement of blood loss: review of the literature. J Midwifery Womens Health 2010; 55:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bose P, Regan F, Paterson-Brown S. Improving the accuracy of estimated blood loss at obstetric haemorrhage using clinical reconstructions. BJOG 2006; 113:919.
          </a>
         </li>
         <li class="breakAll">
          Lyndon A, Miller S, Huwe V, Rosen M, et al. Blood loss: Clinical techniques for ongoing quantitative measurement. California Maternal Quality Care Collaborative. CMQCC Obstetric Hemorrhage Toolkit; 1/6/2010.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerdessen L, Meybohm P, Choorapoikayil S, et al. Comparison of common perioperative blood loss estimation techniques: a systematic review and meta-analysis. J Clin Monit Comput 2021; 35:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diaz V, Abalos E, Carroli G. Methods for blood loss estimation after vaginal birth. Cochrane Database Syst Rev 2018; 9:CD010980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madar H, Sentilhes L, Goffinet F, et al. Comparison of quantitative and calculated postpartum blood loss after vaginal delivery. Am J Obstet Gynecol MFM 2023; 5:101065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prata N, Gerdts C. Measurement of postpartum blood loss. BMJ 2010; 340:c555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li XF, Fortney JA, Kotelchuck M, Glover LH. The postpartum period: the key to maternal mortality. Int J Gynaecol Obstet 1996; 54:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields LE, Wiesner S, Klein C, et al. Use of Maternal Early Warning Trigger tool reduces maternal morbidity. Am J Obstet Gynecol 2016; 214:527.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mhyre JM, DʼOria R, Hameed AB, et al. The maternal early warning criteria: A proposal from the national partnership for maternal safety. Obstet Gynecol 2014; 124:782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Main EK, McCain CL, Morton CH, et al. Pregnancy-related mortality in California: causes, characteristics, and improvement opportunities. Obstet Gynecol 2015; 125:938.
          </a>
         </li>
         <li class="breakAll">
          Saving Lives, Improving Mothers’ Care - Surveillance of maternal deaths in the UK 2012-14 and lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2009-14 https://www.npeu.ox.ac.uk/downloads/files/mbrrace-uk/reports/MBRRACE-UK%20Maternal%20Report%202016%20-%20website.pdf (Accessed on October 23, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonnar J. Massive obstetric haemorrhage. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor D, Fleischer A, Meirowitz N, Rosen L. Shock index and vital-sign reference ranges during the immediate postpartum period. Int J Gynaecol Obstet 2017; 137:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Ayadi AM, Nathan HL, Seed PT, et al. Vital Sign Prediction of Adverse Maternal Outcomes in Women with Hypovolemic Shock: The Role of Shock Index. PLoS One 2016; 11:e0148729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Bas A, Chandraharan E, Addei A, Arulkumaran S. Use of the "obstetric shock index" as an adjunct in identifying significant blood loss in patients with massive postpartum hemorrhage. Int J Gynaecol Obstet 2014; 124:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathan HL, Cottam K, Hezelgrave NL, et al. Determination of Normal Ranges of Shock Index and Other Haemodynamic Variables in the Immediate Postpartum Period: A Cohort Study. PLoS One 2016; 11:e0168535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor D, Fleischer A, Rosen, L . Determining the normal values of shock index, pulse pressure, and ROPE in the immediate postpartum period. Obstet Gynecol 2016; 127:38S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kohn JR, Dildy GA, Eppes CS. Shock index and delta-shock index are superior to existing maternal early warning criteria to identify postpartum hemorrhage and need for intervention. J Matern Fetal Neonatal Med 2019; 32:1238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wikkelsø A, Wetterslev J, Møller AM, Afshari A. Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to monitor haemostatic treatment in bleeding patients: a systematic review with meta-analysis and trial sequential analysis. Anaesthesia 2017; 72:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snegovskikh D, Souza D, Walton Z, et al. Point-of-care viscoelastic testing improves the outcome of pregnancies complicated by severe postpartum hemorrhage. J Clin Anesth 2018; 44:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khanna P, Sinha C, Singh AK, et al. The role of point of care thromboelastography (TEG) and thromboelastometry (ROTEM) in management of Primary postpartum haemorrhage: A meta-analysis and systematic review. Saudi J Anaesth 2023; 17:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kong CW, To WW. Prognostic factors for the use of intrauterine balloon tamponade in the management of severe postpartum hemorrhage. Int J Gynaecol Obstet 2018; 142:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz Labarta FJ, Pintado Recarte MP, Alvarez Luque A, et al. Outcomes of pelvic arterial embolization in the management of postpartum haemorrhage: a case series study and systematic review. Eur J Obstet Gynecol Reprod Biol 2016; 206:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Ayadi AM, Butrick E, Geissler J, Miller S. Combined analysis of the non-pneumatic anti-shock garment on mortality from hypovolemic shock secondary to obstetric hemorrhage. BMC Pregnancy Childbirth 2013; 13:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magwali TL, Butrick E, Ayadi AE, et al. A cluster randomized controlled trial of the non-pneumatic anti-shock garment for obstetric haemorrhage: sub-analysis of the Zimbabwean Arm. Cent Afr J Med 2015; 61:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mbaruku G, Therrien MS, Tillya R, et al. Implementation project of the non-pneumatic anti-shock garment and m-communication to enhance maternal health care in rural Tanzania. Reprod Health 2018; 15:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pileggi-Castro C, Nogueira-Pileggi V, Tunçalp Ö, et al. Non-pneumatic anti-shock garment for improving maternal survival following severe postpartum haemorrhage: a systematic review. Reprod Health 2015; 12:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figo Safe Motherhood and Newborn Health Committee, International Federation of Gynecology and Obstetrics. Non-pneumatic anti-shock garment to stabilize women with hypovolemic shock secondary to obstetric hemorrhage. Int J Gynaecol Obstet 2015; 128:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller S, Hamza S, Bray EH, et al. First aid for obstetric haemorrhage: the pilot study of the non-pneumatic anti-shock garment in Egypt. BJOG 2006; 113:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hauswald M, Williamson MR, Baty GM, et al. Use of an improvised pneumatic anti-shock garment and a non-pneumatic anti-shock garment to control pelvic blood flow. Int J Emerg Med 2010; 3:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geerts WH, Code KI, Jay RM, et al. A prospective study of venous thromboembolism after major trauma. N Engl J Med 1994; 331:1601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thurn L, Wikman A, Lindqvist PG. Postpartum blood transfusion and hemorrhage as independent risk factors for venous thromboembolism. Thromb Res 2018; 165:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang C, Le Ray I, Lee B, et al. Association of blood group and red blood cell transfusion with the incidence of antepartum, peripartum and postpartum venous thromboembolism. Sci Rep 2019; 9:13535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pacheco LD, Saade GR, Gei AF, Hankins GD. Cutting-edge advances in the medical management of obstetrical hemorrhage. Am J Obstet Gynecol 2011; 205:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shakur H, Elbourne D, Gülmezoglu M, et al. The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials 2010; 11:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milman N. Postpartum anemia II: prevention and treatment. Ann Hematol 2012; 91:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuklina EV, Meikle SF, Jamieson DJ, et al. Severe obstetric morbidity in the United States: 1998-2005. Obstet Gynecol 2009; 113:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J. Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: a randomized controlled trial. Vox Sang 2017; 112:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sultan P, Bampoe S, Shah R, et al. Oral vs intravenous iron therapy for postpartum anemia: a systematic review and meta-analysis. Am J Obstet Gynecol 2019; 221:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhandal N, Russell R. Intravenous versus oral iron therapy for postpartum anaemia. BJOG 2006; 113:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anemia during pregnancy and in the postpartum: intravenous iron therapy revisited. Eur J Obstet Gynecol Reprod Biol 2005; 123 Suppl 2:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perelló MF, Coloma JL, Masoller N, et al. Intravenous ferrous sucrose versus placebo in addition to oral iron therapy for the treatment of severe postpartum anaemia: a randomised controlled trial. BJOG 2014; 121:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotto-Kome AC, Calhoun DA, Montenegro R, et al. Effect of administering recombinant erythropoietin to women with postpartum anemia: a meta-analysis. J Perinatol 2004; 24:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wågström E, Akesson A, Van Rooijen M, et al. Erythropoietin and intravenous iron therapy in postpartum anaemia. Acta Obstet Gynecol Scand 2007; 86:957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; 389:2105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdel-Razeq SS, Campbell K, Funai EF, et al. Normative postpartum intraabdominal pressure: potential implications in the diagnosis of abdominal compartment syndrome. Am J Obstet Gynecol 2010; 203:149.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           March CM. Intrauterine adhesions. Obstet Gynecol Clin North Am 1995; 22:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schenker JG. Etiology of and therapeutic approach to synechia uteri. Eur J Obstet Gynecol Reprod Biol 1996; 65:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poujade O, Grossetti A, Mougel L, et al. Risk of synechiae following uterine compression sutures in the management of major postpartum haemorrhage. BJOG 2011; 118:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rasheed SM, Amin MM, Abd Ellah AH, et al. Reproductive performance after conservative surgical treatment of postpartum hemorrhage. Int J Gynaecol Obstet 2014; 124:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rathat G, Do Trinh P, Mercier G, et al. Synechia after uterine compression sutures. Fertil Steril 2011; 95:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ibrahim MI, Raafat TA, Ellaithy MI, Aly RT. Risk of postpartum uterine synechiae following uterine compression suturing during postpartum haemorrhage. Aust N Z J Obstet Gynaecol 2013; 53:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sentilhes L, Gromez A, Clavier E, et al. Long-term psychological impact of severe postpartum hemorrhage. Acta Obstet Gynecol Scand 2011; 90:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parry-Smith W, Okoth K, Subramanian A, et al. Postpartum haemorrhage and risk of mental ill health: A population-based longitudinal study using linked primary and secondary care databases. J Psychiatr Res 2021; 137:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pranal M, Legrand A, de Chazeron I, et al. Prevalence of maternal psychological disorders after immediate postpartum haemorrhage: a repeated cross-sectional study - the PSYCHE* study protoco. BMJ Open 2019; 9:e027390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ricbourg A, Gosme C, Gayat E, et al. Emotional impact of severe post-partum haemorrhage on women and their partners: an observational, case-matched, prospective, single-centre pilot study. Eur J Obstet Gynecol Reprod Biol 2015; 193:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaat TR, van Steijn ME, de Haan-Jebbink JM, et al. Posttraumatic stress disorder related to postpartum haemorrhage: A systematic review. Eur J Obstet Gynecol Reprod Biol 2018; 225:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oberg AS, Hernandez-Diaz S, Palmsten K, et al. Patterns of recurrence of postpartum hemorrhage in a large population-based cohort. Am J Obstet Gynecol 2014; 210:229.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ford JB, Roberts CL, Bell JC, et al. Postpartum haemorrhage occurrence and recurrence: a population-based study. Med J Aust 2007; 187:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiter L, Kazemier BM, Mol BWJ, Pajkrt E. Incidence and recurrence rate of postpartum hemorrhage and manual removal of the placenta: A longitudinal linked national cohort study in The Netherlands. Eur J Obstet Gynecol Reprod Biol 2019; 238:114.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6710 Version 155.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31764790" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Carbetocin vs oxytocin for prevention of postpartum hemorrhage after vaginal delivery: A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33913639" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31437195" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : How well do postpartum blood loss and common definitions of postpartum hemorrhage correlate with postpartum anemia and fall in hemoglobin?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28937571" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Practice Bulletin No. 183: Postpartum Hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28937571" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Practice Bulletin No. 183: Postpartum Hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28937571" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Practice Bulletin No. 183: Postpartum Hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24641530" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Postpartum haemorrhage management, risks, and maternal outcomes: findings from the World Health Organization Multicountry Survey on Maternal and Newborn Health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34497812" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Incidence and Risk Factors of Postpartum Hemorrhage in China: A Multicenter Retrospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36701615" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Postpartum Hemorrhage Trends and Outcomes in the United States, 2000-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25447386" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : [Epidemiology of post-partum haemorrhage].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32530404" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A national update on rates of postpartum haemorrhage and related interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35923676" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Race/Ethnicity as a Risk Factor in the Development of Postpartum Hemorrhage: A Thorough Systematic Review of Disparity in the Relationship Between Pregnancy and the Rate of Postpartum Hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8796825" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A biological model for the regulation of peri-implantational hemostasis and menstruation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8408448" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Steroid-modulated stromal cell tissue factor expression: a model for the regulation of endometrial hemostasis and menstruation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11303186" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Regulation of plasminogen activator inhibitor 1 expression by interaction of epidermal growth factor with progestin during decidualization of human endometrial stromal cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10406075" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The decidua regulates hemostasis in human endometrium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20237047" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The epidemiology of postpartum hemorrhage in a large, nationwide sample of deliveries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16157111" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The MFMU Cesarean Registry: uterine atony after primary cesarean delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19608153" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The association between the length of first stage of labor, mode of delivery, and perinatal outcomes in women undergoing induction of labor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21860284" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Maternal obesity and risk of postpartum hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23507549" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Risk factors for uterine atony/postpartum hemorrhage requiring treatment after vaginal delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23871950" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Incidence, risk factors, and temporal trends in severe postpartum hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24412115" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Intergenerational transmission of postpartum hemorrhage risk: analysis of 2 Scottish birth cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25845914" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Antidepressants during pregnancy and postpartum hemorrhage: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25121825" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Genetic contribution to postpartum haemorrhage in Swedish population: cohort study of 466,686 births.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23126633" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Delays in the delivery room of a primary maternity unit: a retrospective analysis of obstetric outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26374444" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Antidepressant use in late gestation and risk of postpartum haemorrhage: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27981745" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Assisted reproductive technology and severe postpartum haemorrhage: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28068990" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Risk factors for severe postpartum hemorrhage: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32162458" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : SSRI use during pregnancy and risk for postpartum haemorrhage: a national register-based cohort study in Sweden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33760074" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Association of Gestational Age with Postpartum Hemorrhage: An International Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34622946" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Recurrence of postpartum hemorrhage in relatives: A population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16272036" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Obstetric risk factors and outcome of pregnancies complicated with early postpartum hemorrhage: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24201690" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Massive blood transfusion during hospitalization for delivery in New York State, 1998-2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28409600" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Postpartum Hemorrhage: Prevention and Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31567319" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Trends in Postpartum Hemorrhage in the United States From 2010 to 2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27824773" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Prevalence, Indications, Risk Indicators, and Outcomes of Emergency Peripartum Hysterectomy Worldwide: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33417319" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Risk Factors for Atonic Postpartum Hemorrhage: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25923024" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Management of Persistent Postpartum Hemorrhage Caused by Inner Myometrial Lacerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33994274" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The incidence, aetiology, and coagulation management of massive postpartum haemorrhage: a two-year national prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32087423" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Risk factors for severe perineal trauma during childbirth: An updated meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32580653" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Risk factors for uterine incision extension during cesarean delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32580653" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Risk factors for uterine incision extension during cesarean delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23743452" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Clinical validation of risk stratification criteria for peripartum hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31764744" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Evaluation of Risk-Assessment Tools for Severe Postpartum Hemorrhage in Women Undergoing Cesarean Delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36988059" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Comparison of three antepartum risk assessment tools to predict significant postpartum hemorrhage in livebirths.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32575159" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Predicting risk of postpartum haemorrhage: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35918188" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Predicting postpartum haemorrhage: A systematic review of prognostic models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17286771" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Is primary postpartum haemorrhage a good predictor of inherited bleeding disorders?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11251653" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Obstetrical and gynaecological bleeding: a common presenting symptom.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20619388" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Reduction in elective delivery at&lt;39 weeks of gestation: comparative effectiveness of 3 approaches to change and the impact on neonatal intensive care admission and stillbirth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25659468" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Does the presence of a condition-specific obstetric protocol lead to detectable improvements in pregnancy outcomes?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24631441" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Can differences in obstetric outcomes be explained by differences in the care provided? The MFMU Network APEX study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15104617" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Successful reduction of massive postpartum haemorrhage by use of guidelines and staff education.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25025944" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Comprehensive maternal hemorrhage protocols reduce the use of blood products and improve patient safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28885411" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Improvement in Outcomes of Major Obstetric Hemorrhage Through Systematic Change.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22083059" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Comprehensive maternal hemorrhage protocols improve patient safety and reduce utilization of blood products.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33481835" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A total blood volume or more transfused during pregnancy or after childbirth: Individual patient data from six international population-based observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30509680" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Massive hemorrhage protocol activation in obstetrics: a 5-year quality performance review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30865585" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Patient blood management in obstetrics: prevention and treatment of postpartum haemorrhage. A NATA consensus statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37277130" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Nonsurgical management of major hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31407312" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Preventing severe hypocalcemia during surgery for placenta accreta spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29194062" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Cost-effectiveness Analysis of Intraoperative Cell Salvage for Obstetric Hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35247224" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : How do I perform cell salvage during vaginal obstetric hemorrhage?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34052191" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Does simulation improve clinical performance in management of postpartum hemorrhage?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35238018" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Nationwide confidential enquiries into maternal deaths because of obstetric hemorrhage in the Netherlands between 2006 and 2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37158447" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Randomized Trial of Early Detection and Treatment of Postpartum Hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20129226" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Measurement of blood loss: review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16907938" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Improving the accuracy of estimated blood loss at obstetric haemorrhage using clinical reconstructions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16907938" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Improving the accuracy of estimated blood loss at obstetric haemorrhage using clinical reconstructions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32815042" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Comparison of common perioperative blood loss estimation techniques: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30211952" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Methods for blood loss estimation after vaginal birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37356572" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Comparison of quantitative and calculated postpartum blood loss after vaginal delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20123836" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Measurement of postpartum blood loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8842811" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : The postpartum period: the key to maternal mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26924745" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Use of Maternal Early Warning Trigger tool reduces maternal morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25198266" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : The maternal early warning criteria: A proposal from the national partnership for maternal safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25751214" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Pregnancy-related mortality in California: causes, characteristics, and improvement opportunities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25751214" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Pregnancy-related mortality in California: causes, characteristics, and improvement opportunities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10789257" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Massive obstetric haemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28196269" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Shock index and vital-sign reference ranges during the immediate postpartum period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26901161" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Vital Sign Prediction of Adverse Maternal Outcomes in Women with Hypovolemic Shock: The Role of Shock Index.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24373705" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Use of the "obstetric shock index" as an adjunct in identifying significant blood loss in patients with massive postpartum hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27997586" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Determination of Normal Ranges of Shock Index and Other Haemodynamic Variables in the Immediate Postpartum Period: A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Determining the normal values of shock index, pulse pressure, and ROPE in the immediate postpartum period
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29113517" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Shock index and delta-shock index are superior to existing maternal early warning criteria to identify postpartum hemorrhage and need for intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28052313" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to monitor haemostatic treatment in bleeding patients: a systematic review with meta-analysis and trial sequential analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29121548" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Point-of-care viscoelastic testing improves the outcome of pregnancies complicated by severe postpartum hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37032697" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : The role of point of care thromboelastography (TEG) and thromboelastometry (ROTEM) in management of Primary postpartum haemorrhage: A meta-analysis and systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29603742" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Prognostic factors for the use of intrauterine balloon tamponade in the management of severe postpartum hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27612214" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Outcomes of pelvic arterial embolization in the management of postpartum haemorrhage: a case series study and systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24237656" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Combined analysis of the non-pneumatic anti-shock garment on mortality from hypovolemic shock secondary to obstetric hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29144074" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : A cluster randomized controlled trial of the non-pneumatic anti-shock garment for obstetric haemorrhage: sub-analysis of the Zimbabwean Arm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30340602" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Implementation project of the non-pneumatic anti-shock garment and m-communication to enhance maternal health care in rural Tanzania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25889868" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Non-pneumatic anti-shock garment for improving maternal survival following severe postpartum haemorrhage: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25467912" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Non-pneumatic anti-shock garment to stabilize women with hypovolemic shock secondary to obstetric hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16553654" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : First aid for obstetric haemorrhage: the pilot study of the non-pneumatic anti-shock garment in Egypt.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21031041" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Use of an improvised pneumatic anti-shock garment and a non-pneumatic anti-shock garment to control pelvic blood flow.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7969340" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : A prospective study of venous thromboembolism after major trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29573720" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Postpartum blood transfusion and hemorrhage as independent risk factors for venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31537816" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Association of blood group and red blood cell transfusion with the incidence of antepartum, peripartum and postpartum venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21816382" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Cutting-edge advances in the medical management of obstetrical hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20398351" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22160256" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Postpartum anemia II: prevention and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19155897" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Severe obstetric morbidity in the United States: 1998-2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28198084" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30578747" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Oral vs intravenous iron therapy for postpartum anemia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17004982" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Intravenous versus oral iron therapy for postpartum anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16360535" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Anemia during pregnancy and in the postpartum: intravenous iron therapy revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24423186" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Intravenous ferrous sucrose versus placebo in addition to oral iron therapy for the treatment of severe postpartum anaemia: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14726931" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Effect of administering recombinant erythropoietin to women with postpartum anemia: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17653881" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Erythropoietin and intravenous iron therapy in postpartum anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28456509" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20417482" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Normative postpartum intraabdominal pressure: potential implications in the diagnosis of abdominal compartment syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8524533" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Intrauterine adhesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8706941" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Etiology of and therapeutic approach to synechia uteri.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21199289" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Risk of synechiae following uterine compression sutures in the management of major postpartum haemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24380610" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Reproductive performance after conservative surgical treatment of postpartum hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20883989" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Synechia after uterine compression sutures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23163583" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Risk of postpartum uterine synechiae following uterine compression suturing during postpartum haemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21370999" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Long-term psychological impact of severe postpartum hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33774536" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Postpartum haemorrhage and risk of mental ill health: A population-based longitudinal study using linked primary and secondary care databases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31488469" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Prevalence of maternal psychological disorders after immediate postpartum haemorrhage: a repeated cross-sectional study - the PSYCHE* study protoco.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26298809" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Emotional impact of severe post-partum haemorrhage on women and their partners: an observational, case-matched, prospective, single-centre pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29747143" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Posttraumatic stress disorder related to postpartum haemorrhage: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24351791" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Patterns of recurrence of postpartum hemorrhage in a large population-based cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17908001" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Postpartum haemorrhage occurrence and recurrence: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31129559" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Incidence and recurrence rate of postpartum hemorrhage and manual removal of the placenta: A longitudinal linked national cohort study in The Netherlands.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
